科研人员发现相关糖尿病基因

2007年4月27日

美国和欧洲的研究人员发现了与最普通的糖尿病有关的一组基因。在星期四出版的美国《科
学》和《自然遗传学》
杂志的系列文章中，研究人员说，他们已经确认出至少7种可以增加人
类患二型糖尿病风险的新基因。科学家测试
了几个国家的数十万人的dna数据，确认出上述基
因。

科学家希望，新的发现可以让他们研制新的药品来医疗、甚至防止糖尿病的发生。二型糖尿\
病
患者体内不能产生足
够的胰岛素或不能有效利用体内的胰导素。胰岛素把人体内的糖份转换
成能量。二型糖尿病患者还有爆发心脏病、
肾衰竭、失明和肢体坏死等多种疾病的风险。全
世界目前大约有2亿糖尿病患者。

糖尿病干细胞疗法获突\
破 或告别胰岛素治疗

2007年04月13日 08:05:08

 
新华网北京４月１２日\
专电 
据《美国医学会杂志》\
１１日公布的临床试验\
结果，经过干
细胞治疗的糖尿病患者\
在自身体内开始再度自\
然分泌胰岛素之后，已\
经能够停止胰岛素注
射。这种治疗方法堪称\
糖尿病治疗领域的一场\
革命，为证明干细胞对\
Ｉ型糖尿病的疗效提供
了第一个临床证据。

在一次突破性的临床试\
验中，１５名新近诊断\
为Ｉ型糖尿病的年轻患\
者首先服用了一些有遏
制免疫作用的药物，然\
后再在体内移植从自身\
血液中提取的干细胞。

Ｉ型糖尿病患者为控制\
血糖不得不每天注射胰\
岛素，有的甚至一天要\
注射４次，因为其自身
免疫系统紊乱导致体内\
不能自然分泌胰岛素。\
试验结果显示，通过植\
入自身干细胞，这些有
胰岛素依赖的糖尿病患\
者能够摆脱对胰岛素注\
射的依赖。

这次临床试验的结果表\
明，除两名患者外，其\
他所有自愿参加试验的\
患者在停止其他治疗之
后可以在最长达３年期\
间不必注射胰岛素。

由巴西和美国科学家联\
合进行的这项新研究发\
现，首批接受这种治疗\
的患者之一已经在３年
内不再接受其他任何辅\
助性的胰岛素治疗了。\
他们在报告中说："在&#20026\
;数不多的早期得病的
患者中已取得了十分令\
人鼓舞的结果。９３％\
的病人在不同阶段摆脱\
了对胰岛素的依赖，治
疗的毒副作用很少见，\
没有一人死亡。"

这个研究小组希望利用\
干细胞对病人进行早期\
干预，从而能彻底治愈\
糖尿病并恢复患者正常
的免疫系统。

参加最新试验的英国糖\
尿病患者的年龄在１４\
岁至３１岁之间，而且\
都是在试验前６周内被
诊断为糖尿病患者。在\
自身体内抽取干细胞之\
后，他们需要进行温和\
的化疗，以杀灭给胰腺
造成破坏的白血球。随\
后他们再接受自身干细\
胞的移植，以帮助恢复\
自身免疫系统功能。

    
这份研究报告的作者之\
一、来自美国西北大学\
范伯格医学院的理查德\
�伯特说，接受试
验的１５名患者中有１\
４人在接受治疗后的一\
段时间内停用了胰岛素\
，其中１１人移植干细
胞后立即就能分泌起补\
充作用的胰岛素，而且\
自此就不再求助于合成\
胰岛素了。

Stem Cell Therapy May Combat Type 1 Diabetes

Small trial offers hope, but much more research is needed, experts
say

http://www.nlm.nih.gov/medlineplus/news/fullstory_47733.html

Tuesday, April 10, 2007

TUESDAY, April 10 (HealthDay News) -- A pilot study of people newly
diagnosed with type 1 diabetes found that stem cell therapy
eliminated the need for insulin therapy for varying periods of time.
This is the first trial to look at stem cell therapy in humans with
this form of the disease. But experts stressed that the research is
preliminary and urged caution when interpreting the results, which
are published in the April 11 issue of the Journal of the American
Medical Association.

"This may be the first step in something that could be promising, but
I need to see a control group and longer follow-up before I'd go out
on a limb," said Dr. Jay S. Skyler, author of an accompanying
editorial in the journal and associate director of the Diabetes
Research Institute at the University of Miami Miller School of
Medicine. "But this is worthy of further experimentation."

Type 1 diabetes develops when the body's immune system attacks the
pancreatic beta cells, which produce insulin -- the hormone that
transports sugar from the blood to cells for energy.

"In type 1 diabetes, the immune system is out of balance," Skyler
explained. "Ordinarily, all of us have some cells with the potential
to destroy the pancreas, but the regulatory immune system prevents
those cells from becoming sufficiently active. In type 1 (diabetes),
there's a greater proportion of activity of the destroying cells and
lesser activity of the regulatory cells. The goal is to try to bring
that back into balance."

By the time a person is diagnosed with the disease, some 60 percent
to 80 percent of the beta cells have already been destroyed. And
people who have more functioning beta cells tend to have fewer
complications down the line, research has shown.

Immunosuppression therapy, designed to dampen the immune system, can
help, but these patients still need to take insulin to regulate their
blood sugar. Meanwhile, stem cell therapy has had some success with
other autoimmune diseases, such as lupus, but not with type 1
diabetes.

"There has been use of this specific procedure in other autoimmune
disease in human beings with some suggestion of promise of effect,
and it's been advocated for a number of years that this kind of
approach might be useful in type 1 diabetes," Skyler said.

The new study, conducted by scientists in Sao Paolo, Brazil, and in
Chicago, involved 15 patients newly diagnosed with type 1 diabetes.
All participants underwent high-dose immunosuppression therapy
followed by a procedure called autologous nonmyeloablative
hematopoietic stem cell transplantation (AHST) to preserve beta-cell
function.

AHST involves removing a patient's own blood stem cells, treating
them, and then returning them to the patient.

"Using bone marrow precursor cells, which are precursors of immune T-
cells, is designed to reset the immune system," Skyler said. "The
reason for choosing a point early in time is that you want to have
enough beta cells that are still left."

During follow-up that lasted up to 36 months, 93 percent of the
patients achieved some length of insulin independence. Fourteen
patients became insulin free -- one for 35 months, four for at least
21 months, seven for at least six months. Two more participants who
had late responses to the stem cell therapy became insulin free for
one and five months, respectively.

One person developed pneumonia, and two others developed problems
with their endocrine system, which governs hormones in the body.
It's unclear exactly how the stem cell transplants worked their
magic. And there are still numerous questions.

"The obvious question is how long does it work and what is the risk
of treatment," said Dr. Larry Deeb, president of medicine and science
at the American Diabetes Association. "But the excitement is where we
are in diabetes research and treatment, and the excitement some of
these questions generate for people who have diabetes and for the
diabetes community and for the profound argument that this is not a
time to be proposing less money for research in diabetes."

Yiqindin biri weten ichidin bezi dostlar manga xet yizip diyabit
kisilini dawalashta heqiqeten chong ilgirlesh bolghan
bolmighanlighini sorighan idi.

Mining buningha jawabim towendikiche: NIH (Amirka dowletlik tibbi
penler akidimiyesi) ning 2007-yili 4-ayning 10-kunidiki xewerde bayan
qilishiche, 1-tiptiki diyabit kisilini ghol hujeyrisi bilen dawalash
arqiliq deslepki qedemde bezi unumge irishken bolup, bu xil
dawalashning unimi yenimu ilgirligen halda sinaq qilishqa muxtaj
iken. Yeni dimekchi bolghunum bu xil dawalash usulining diyabit
kisilige giriptar bolghan bimarlar arisida keng kolemde ishlitilishke
yene bir mezgil waqit kirek.

Ghol hujeyrisi bilen diyabit kisilini dawalap deslepki qedemde
muhapiqiyet qazinishning ozi diyabit kisilini dawalash tarixida
insulindin kiyinki yene bir zor inqilap hisaplinidu.

Esli igilizche xewerde, “Stem Cell Therapy May Combat Type 1
Diabetes. Small trial offers hope, but much more research is needed”
yeni “ghol hujeyrisi 1-turdiki diyabit kisilige jeng ilan qilishi
mumkin. Kichikine sinaq umut chirighini yaqti, biraq yenimu
ilgirligen halda tetqiq qilishqa muxtaj” diyilgen bolup, Junguoda
birilgen xewerde, “糖尿病干细胞疗法获突破 或告别胰岛素治疗”, yeni “Ghol
hujeyre bilen diyabit kisilini dawalash muhapiqiyetke irishti,
insulin bilen hoshlishishi mumkin” diyilgen.

Towende men dostlarning paydilinishi uchun bu xewerning ikkisini
herqaysinglargha sundum.

美报称多起糖浆中毒事件源于中国

据《纽约时报》报道，在过去的20年中，有8起大规模中毒事件是由于有毒糖浆造成的，调瞈
槿嗽�
发现有成千上万人死于中毒事件。有关证据显示，在过去四起中毒事件中有三起是源于中国\
。

报道称，在过去几年中，在工业中使用的溶剂二甘醇被以糖浆名义掺入到各种药物中，比如\
咳嗽
糖浆，感冒药，以及注射剂等药物。

最近一起中毒事件发生在巴拿马。去年，政府官员在不知情的情况下把实为二甘醇的"糖浆"\
掺入
了26万瓶感冒药中。

结果，据报有365名病人在服用该批药物后死亡，其中100例被确认为中毒死亡病例。

巴拿马的雨季即将来临，调查人员正在加快速度以在更多的尸体被掩埋之前发掘尽可能多的\
可能
死于毒糖浆的尸体来化验死因。

巴拿马中毒事件的直接肇事者是制造并出口这批二甘醇的中国公司，他们把这批货称为纯度\
为
99.5%的甘油。

《纽约时报》指出，这46桶有毒糖浆从长江三角洲经北京，巴塞罗那运到巴拿马港口城市固\
朗。

报道称，这批有毒糖浆途径三大洲的三个贸易公司，但是没有任何一家公司对这批货物商标\
上所
称的成份进行检验。

有关货物成份的文件几经改动，制造商以及货物主人的名字也被抹掉。这样，购买货物的一\
方都
不知道货物源自哪里。

该报称，就去年发生的两期中毒事件中，-
巴拿马和中国齐齐哈尔的二甘醇导致民众死亡的事件
的测试显示，中国正快速成为世界上廉价原料供应商，但是其安全规定的发展却远远不够。

美国当局在早些时候已经谴责中国出口的面筋中含有工业化学元素三聚氰胺。这种面筋使用\
在宠
物食品以及牲畜饲料中。

除了巴拿马和中国之外，有毒糖浆在海地，孟加拉国，阿根廷，尼日利亚以及两度在印度造\
成了
严重的中毒事件。


BBC中文网报道

New York Times gizitige bisilghan towendiki bu xewerde Jungguoda
ishlengen bezi zeher terkiwi bar layaqetsiz dorilar sewibidin
kishilerning olup kitishini kelturup chiqarghanliqqa ahit mesililer
bayan qilinghan bolup, oqup qoyushqa erzidiken.

http://www.nytimes.com/2007/05/06/world/americas/06poison.html?
_r=1&th&emc=th&oref=slogin

May 6, 2007

From China to Panama, a Trail of Poisoned Medicine

By WALT BOGDANICH and JAKE HOOKER

The kidneys fail first. Then the central nervous system begins to
misfire. Paralysis spreads, making breathing difficult, then often
impossible without assistance. In the end, most victims die.
Many of them are children, poisoned at the hands of their
unsuspecting parents.

The syrupy poison, diethylene glycol, is an indispensable part of
the modern world, an industrial solvent and prime ingredient in some
antifreeze.

It is also a killer. And the deaths, if not intentional, are often
no accident.

Over the years, the poison has been loaded into all varieties of
medicine � cough syrup, fever medication, injectable drugs � a
result of counterfeiters who profit by substituting the sweet-
tasting solvent for a safe, more expensive syrup, usually glycerin,
commonly used in drugs, food, toothpaste and other products.
Toxic syrup has figured in at least eight mass poisonings around the
world in the past two decades. Researchers estimate that thousands
have died. In many cases, the precise origin of the poison has never
been determined. But records and interviews show that in three of
the last four cases it was made in China, a major source of
counterfeit drugs.

Panama is the most recent victim. Last year, government officials
there unwittingly mixed diethylene glycol into 260,000 bottles of
cold medicine � with devastating results. Families have reported 365
deaths from the poison, 100 of which have been confirmed so far.
With the onset of the rainy season, investigators are racing to
exhume as many potential victims as possible before bodies decompose
even more.

Panama's death toll leads directly to Chinese companies that made
and exported the poison as 99.5 percent pure glycerin.

Forty-six barrels of the toxic syrup arrived via a poison pipeline
stretching halfway around the world. Through shipping records and
interviews with government officials, The New York Times traced this
pipeline from the Panamanian port of Col髇, back through trading
companies in Barcelona, Spain, and Beijing, to its beginning near
the Yangtze Delta in a place local people call "chemical country."
The counterfeit glycerin passed through three trading companies on
three continents, yet not one of them tested the syrup to confirm
what was on the label. Along the way, a certificate falsely
attesting to the purity of the shipment was repeatedly altered,
eliminating the name of the manufacturer and previous owner. As a
result, traders bought the syrup without knowing where it came from,
or who made it. With this information, the traders might have
discovered � as The Times did � that the manufacturer was not
certified to make pharmaceutical ingredients.

An examination of the two poisoning cases last year � in Panama and
earlier in China � shows how China's safety regulations have lagged
behind its growing role as low-cost supplier to the world. It also
demonstrates how a poorly policed chain of traders in country after
country allows counterfeit medicine to contaminate the global market.
Last week, the United States Food and Drug Administration warned
drug makers and suppliers in the United States "to be especially
vigilant" in watching for diethylene glycol. The warning did not
specifically mention China, and it said there was "no reason to
believe" that glycerin in this country was tainted. Even so, the
agency asked that all glycerin shipments be tested for diethylene
glycol, and said it was "exploring how supplies of glycerin become
contaminated."

China is already being accused by United States authorities of
exporting wheat gluten containing an industrial chemical, melamine,
that ended up in pet food and livestock feed. The F.D.A. recently
banned imports of Chinese-made wheat gluten after it was linked to
pet deaths in the United States.

Beyond Panama and China, toxic syrup has caused mass poisonings in
Haiti, Bangladesh, Argentina, Nigeria and twice in India.
In Bangladesh, investigators found poison in seven brands of fever
medication in 1992, but only after countless children died. A
Massachusetts laboratory detected the contamination after Dr.
Michael L. Bennish, a pediatrician who works in developing
countries, smuggled samples of the tainted syrup out of the country
in a suitcase. Dr. Bennish, who investigated the Bangladesh epidemic
and helped write a 1995 article about it for BMJ, formerly known as
the British Medical Journal, said that given the amount of
medication distributed, deaths "must be in the thousands or tens of
thousands."

"It's vastly underreported," Dr. Bennish said of diethylene glycol
poisoning. Doctors might not suspect toxic medicine, particularly in
poor countries with limited resources and a generally unhealthy
population, he said, adding, "Most people who die don't come to a
medical facility."

The makers of counterfeit glycerin, which superficially looks and
acts like the real thing but generally costs considerably less, are
rarely identified, much less prosecuted, given the difficulty of
tracing shipments across borders. "This is really a global problem,
and it needs to be handled in a global way," said Dr. Henk Bekedam,
the World Health Organization's top representative in Beijing.
Seventy years ago, medicine laced with diethylene glycol killed more
than 100 people in the United States, leading to the passage of the
toughest drug regulations of that era and the creation of the modern
Food and Drug Administration.

The F.D.A. has tried to help in poisoning cases around the world,
but there is only so much it can do.

When at least 88 children died in Haiti a decade ago, F.D.A.
investigators traced the poison to the Manchurian city of Dalian,
but their attempts to visit the suspected manufacturer were
repeatedly blocked by Chinese officials, according to internal State
Department records. Permission was granted more than a year later,
but by then the plant had moved and its records had been destroyed.
"Chinese officials we contacted on this matter were all reluctant to
become involved," the American Embassy in Beijing wrote in a
confidential cable. "We cannot be optimistic about our chances for
success in tracking down the other possible glycerine shipments."
In fact, The Times found records showing that the same Chinese
company implicated in the Haiti poisoning also shipped about 50 tons
of counterfeit glycerin to the United States in 1995. Some of it was
later resold to another American customer, Avatar Corporation,
before the deception was discovered.

"Thank God we caught it when we did," said Phil Ternes, chief
operating officer of Avatar, a Chicago-area supplier of bulk
pharmaceuticals and nonmedicinal products. The F.D.A. said it was
unaware of the shipment.

In China, the government is vowing to clean up its pharmaceutical
industry, in part because of criticism over counterfeit drugs
flooding the world markets. In December, two top drug regulators
were arrested on charges of taking bribes to approve drugs. In
addition, 440 counterfeiting operations were closed down last year,
the World Health Organization said.

But when Chinese officials investigated the role of Chinese
companies in the Panama deaths, they found that no laws had been
broken, according to an official of the nation's drug enforcement
agency. China's drug regulation is "a black hole," said one trader
who has done business through CNSC Fortune Way, the Beijing-based
broker that investigators say was a crucial conduit for the Panama
poison.

In this environment, Wang Guiping, a tailor with a ninth-grade
education and access to a chemistry book, found it easy to enter the
pharmaceutical supply business as a middleman. He quickly discovered
what others had before him: that counterfeiting was a simple way to
increase profits.

And then people in China began to die.

Cheating the System
Mr. Wang spent years as a tailor in the manufacturing towns of the
Yangtze Delta, in eastern China. But he did not want to remain a
common craftsman, villagers say. He set his sights on trading
chemicals, a business rooted in the many small chemical plants that
have sprouted in the region.
"He didn't know what he was doing," Mr. Wang's older brother, Wang
Guoping, said in an interview. "He didn't understand chemicals."
But he did understand how to cheat the system.
Wang Guiping, 41, realized he could earn extra money by substituting
cheaper, industrial-grade syrup � not approved for human
consumption � for pharmaceutical grade syrup. To trick
pharmaceutical buyers, he forged his licenses and laboratory
analysis reports, records show.
Mr. Wang later told investigators that he figured no harm would come
from the substitution, because he initially tested a small quantity.
He did it with the expertise of a former tailor.
He swallowed some of it. When nothing happened, he shipped it.
One company that used the syrup beginning in early 2005 was Qiqihar
No. 2 Pharmaceutical, about 1,000 miles away in Heilongjiang
Province in the northeast. A buyer for the factory had seen a
posting for Mr. Wang's syrup on an industry Web site.
After a while, Mr. Wang set out to find an even cheaper substitute
syrup so he could increase his profit even more, according to a
Chinese investigator. In a chemical book he found what he was
looking for: another odorless syrup � diethylene glycol. At the
time, it sold for 6,000 to 7,000 yuan a ton, or about $725 to $845,
while pharmaceutical-grade syrup cost 15,000 yuan, or about $1,815,
according to the investigator.
Mr. Wang did not taste-test this second batch of syrup before
shipping it to Qiqihar Pharmaceutical, the government investigator
said, adding, "He knew it was dangerous, but he didn't know that it
could kill."
The manufacturer used the toxic syrup in five drug products: ampules
of Amillarisin A for gall bladder problems; a special enema fluid
for children; an injection for blood vessel diseases; an intravenous
pain reliever; and an arthritis treatment.
In April 2006, one of southern China's finest hospitals, in
Guangzhou, Guangdong Province, began administering Amillarisin A.
Within a month or so, at least 18 people had died after taking the
medicine, though some had already been quite sick.
Zhou Jianhong, 33, said his father took his first dose of
Amillarisin A on April 19. A week later he was in critical
condition. "If you are going to die, you want to die at home," Mr.
Zhou said. "So we checked him out of the hospital." He died the next
day.
"Everybody wants to invest in the pharmaceutical industry and it is
growing, but the regulators can't keep up," Mr. Zhou said. "We need
a system to assure our safety."
The final death count is unclear, since some people who took the
medicine may have died in less populated areas.
In a small town in Sichuan Province, a man named Zhou Lianghui said
the authorities would not acknowledge that his wife had died from
taking tainted Amillarisin A. But Mr. Zhou, 38, said he matched the
identification number on the batch of medicine his wife received
with a warning circular distributed by drug officials.
"You probably cannot understand a small town if you are in Beijing,"
Zhou Lianghui said in a telephone interview. "The sky is high, and
the emperor is far away. There are a lot of problems here that the
law cannot speak to."
The failure of the government to stop poison from contaminating the
drug supply caused one of the bigger domestic scandals of the year.
Last May, China's premier, Wen Jiabao, ordered an investigation of
the deaths, declaring, "The pharmaceutical market is in disorder."
At about the same time, 9,000 miles away in Panama, the long rainy
season had begun. Anticipating colds and coughs, the government
health program began manufacturing cough and antihistamine syrup.
The cough medicine was sugarless so that even diabetics could use it.
The medicine was mixed with a pale yellow, almost translucent syrup
that had arrived in 46 barrels from Barcelona on the container ship
Tobias Maersk. Shipping records showed the contents to be 99.5
percent pure glycerin.
It would be months and many deaths later before that certification
was discovered to be pure fiction.
A Mysterious Illness
Early last September, doctors at Panama City's big public hospital
began to notice patients exhibiting unusual symptoms.
They initially appeared to have Guillain-Barr� syndrome, a
relatively rare neurological disorder that first shows up as a
weakness or tingling sensation in the legs. That weakness often
intensifies, spreading upward to the arms and chest, sometimes
causing total paralysis and an inability to breathe.
The new patients had paralysis, but it did not spread upward. They
also quickly lost their ability to urinate, a condition not
associated with Guillain-Barr�. Even more unusual was the number of
cases. In a full year, doctors might see eight cases of Guillain-
Barr�, yet they saw that many in just two weeks.
Doctors sought help from an infectious disease specialist, N閟tor
Sosa, an intense, driven doctor who competes in triathlons and high-
level chess.
Dr. Sosa's medical specialty had a long, rich history in Panama,
once known as one of the world's unhealthiest places. In one year in
the late 1800s, a lethal mix of yellow fever and malaria killed
nearly 1 in every 10 residents of Panama City. Only after the United
States managed to overcome those mosquito-borne diseases was it able
to build the Panama Canal without the devastation that undermined an
earlier attempt by the French.
The suspected Guillain-Barr� cases worried Dr. Sosa. "It was
something really extraordinary, something that was obviously
reaching epidemic dimensions in our hospital," he said.
With the death rate from the mystery illness near 50 percent, Dr.
Sosa alerted the hospital management, which asked him to set up and
run a task force to handle the situation. The assignment, a daunting
around-the-clock dash to catch a killer, was one he eagerly
embraced.
Several years earlier, Dr. Sosa had watched as other doctors
identified the cause of another epidemic, later identified as
hantavirus, a pathogen spread by infected rodents.
"I took care of patients but I somehow felt I did not do enough," he
said. The next time, he vowed, would be different.
Dr. Sosa set up a 24-hour "war room" in the hospital, where doctors
could compare notes and theories as they scoured medical records for
clues.
As a precaution, the patients with the mystery illness were
segregated and placed in a large empty room awaiting renovation.
Health care workers wore masks, heightening fears in the hospital
and the community.
"That spread a lot of panic," said Dr. Jorge Motta, a cardiologist
who runs the Gorgas Memorial Institute, a widely respected medical
research center in Panama. "That is always a terrifying thought,
that you will be the epicenter of a new infectious disease, and
especially a new infectious disease that kills with a high rate of
death, like this."
Meanwhile, patients kept coming, and hospital personnel could barely
keep up.
"I ended up giving C.P.R.," Dr. Sosa said. "I haven't given C.P.R.
since I was a resident, but there were so many crises going on."
Frightened hospital patients had to watch others around them die for
reasons no one understood, fearing that they might be next.
As reports of strange Guillain-Barr� symptoms started coming in from
other parts of the country, doctors realized they were not just
dealing with a localized outbreak.
Pascuala P閞ez de Gonz醠ez, 67, sought treatment for a cold at a
clinic in Cocl� Province, about a three-hour drive from Panama City.
In late September she was treated and sent home. Within days, she
could no longer eat; she stopped urinating and went into
convulsions.
A decision was made to take her to the public hospital in Panama
City, but on the way she stopped breathing and had to be
resuscitated. She arrived at the hospital in a deep coma and later
died.
Medical records contained clues but also plenty of false leads.
Early victims tended to be males older than 60 and diabetic with
high blood pressure. About half had been given Lisinopril, a blood
pressure medicine distributed by the public health system.
But many who did not receive Lisinopril still got sick. On the
chance that those patients might have forgotten that they had taken
the drug, doctors pulled Lisinopril from pharmacy shelves � only to
return it after tests found nothing wrong.
Investigators would later discover that Lisinopril did play an
important, if indirect role in the epidemic, but not in the way they
had imagined.
A Major Clue
One patient of particular interest to Dr. Sosa came into the
hospital with a heart attack, but no Guillain-Barr�-type symptoms.
While undergoing treatment, the patient received several drugs,
including Lisinopril. After a while, he began to exhibit the same
neurological distress that was the hallmark of the mystery illness.
"This patient is a major clue," Dr. Sosa recalled saying. "This is
not something environmental, this is not a folk medicine that's been
taken by the patients at home. This patient developed the disease in
the hospital, in front of us."
Soon after, another patient told Dr. Sosa that he, too, developed
symptoms after taking Lisinopril, but because the medicine made him
cough, he also took cough syrup � the same syrup, it turned out,
that had been given to the heart patient.
"I said this has got to be it," Dr. Sosa recalled. "We need to
investigate this cough syrup."
The cough medicine had not initially aroused much suspicion because
many victims did not remember taking it. "Twenty-five percent of
those people affected denied that they had taken cough syrup,
because it's a nonevent in their lives," Dr. Motta said.
Investigators from the United States Centers for Disease Control and
Prevention, who were in Panama helping out, quickly put the bottles
on a government jet and flew them to the United States for testing.
The next day, Oct. 11, as Panamanian health officials were attending
a news conference, a Blackberry in the room went off.
The tests, the C.D.C. was reporting, had turned up diethylene glycol
in the cough syrup.
The mystery had been solved. The barrels labeled glycerin turned out
to contain poison.
Dr. Sosa's exhilaration at learning the cause did not last
long. "It's our medication that is killing these people," he said he
thought. "It's not a virus, it's not something that they got
outside, but it was something we actually manufactured."
A nationwide campaign was quickly begun to stop people from using
the cough syrup. Neighborhoods were searched, but thousands of
bottles either had been discarded or could not be found.
As the search wound down, two major tasks remained: count the dead
and assign blame. Neither has been easy.
A precise accounting is all but impossible because, medical
authorities say, victims were buried before the cause was known, and
poor patients might not have seen doctors.
Another problem is that finding traces of diethylene glycol in
decomposing bodies is difficult at best, medical experts say.
Nonetheless, an Argentine pathologist who has studied diethylene
glycol poisonings helped develop a test for the poison in exhumed
bodies. Seven of the first nine bodies tested showed traces of the
poison, Panamanian authorities said.
With the rainy season returning, though, the exhumations are about
to end. Dr. Jos� Vicente Pachar, director of Panama's Institute of
Legal Medicine and Forensic Sciences, said that as a scientist he
would like a final count of the dead. But he added, "I should accept
the reality that in the case of Panama we are not going to know the
exact number."
Local prosecutors have made some arrests and are investigating
others connected to the case, including officials of the import
company and the government agency that mixed and distributed the
cold medicine. "Our responsibilities are to establish or discover
the truth," said Dimas Guevara, the homicide investigator guiding
the inquiry.
But prosecutors have yet to charge anyone with actually making the
counterfeit glycerin. And if the Panama investigation unfolds as
other inquiries have, it is highly unlikely that they ever will.
A Suspect Factory
Panamanians wanting to see where their toxic nightmare began could
look up the Web site of the company in Hengxiang, China, that
investigators in four countries have identified as having made the
syrup � the Taixing Glycerine Factory. There, under the words "About
Us," they would see a picture of a modern white building nearly a
dozen stories tall, adorned by three arches at the entrance. The
factory, the Web site boasts, "can strictly obey the contract and
keep its word."
But like the factory's syrup, all is not as it seems.
There are no tall buildings in Hengxiang, a country town with one
main road. The factory is not certified to sell any medical
ingredients, Chinese officials say. And it looks nothing like the
picture on the Internet. In reality, its chemicals are mixed in a
plain, one-story brick building.
The factory is in a walled compound, surrounded by small shops and
farms. In the spring, nearby fields of rape paint the countryside
yellow. Near the front gate, a sign over the road warns, "Beware of
counterfeits." But it was posted by a nearby noodle machine factory
that appears to be worried about competition.
The Taixing Glycerine Factory bought its diethylene glycol from the
same manufacturer as Mr. Wang, the former tailor, the government
investigator said. From this spot in China's chemical country, the
46 barrels of toxic syrup began their journey, passing from company
to company, port to port and country to country, apparently without
anyone testing their contents.
Traders should be thoroughly familiar with their suppliers, United
States health officials say. "One simply does not assume that what
is labeled is indeed what it is," said Dr. Murray Lumpkin, deputy
commissioner for international and special programs for the Food and
Drug Administration.
In the Panama case, names of suppliers were removed from shipping
documents as they passed from one entity to the next, according to
records and investigators. That is a practice some traders use to
prevent customers from bypassing them on future purchases, but it
also hides the provenance of the product.
The first distributor was the Beijing trading company, CNSC Fortune
Way, a unit of a state-owned business that began by supplying goods
and services to Chinese personnel and business officials overseas.
As China's market reach expanded, Fortune Way focused its business
on pharmaceutical ingredients, and in 2003, it brokered the sale of
the suspect syrup made by the Taixing Glycerine Factory. The
manufacturer's certificate of analysis showed the batch to be 99.5
percent pure.
Whether the Taixing Glycerine Factory actually performed the test
has not been publicly disclosed.
Original certificates of analysis should be passed on to each new
buyer, said Kevin J. McGlue, a board member of the International
Pharmaceutical Excipients Council. In this case, that was not done.
Fortune Way translated the certificate into English, putting its
name � not the Taixing Glycerine Factory's � at the top of the
document, before shipping the barrels to a second trading company,
this one in Barcelona.
Li Can, managing director at Fortune Way, said he did not remember
the transaction and could not comment, adding, "There is a high
volume of trade."
Upon receiving the barrels in September 2003, the Spanish company,
Rasfer International, did not test the contents, either. It copied
the chemical analysis provided by Fortune Way, then put its logo on
it. Ascensi髇 Criado, Rasfer's manager, said in an e-mail response
to written questions that when Fortune Way shipped the syrup, it did
not say who made it.
Several weeks later, Rasfer shipped the drums to a Panamanian
broker, the Medicom Business Group. "Medicom never asked us for the
name of the manufacturer," Ms. Criado said.
A lawyer for Medicom, Valent韓 Ja閚, said his client was a victim,
too. "They were tricked by somebody," Mr. Ja閚 said. "They operated
in good faith."
In Panama, the barrels sat unused for more than two years, and
officials said Medicom improperly changed the expiration date on the
syrup.
During that time, the company never tested the product. And the
Panamanian government, which bought the 46 barrels and used them to
make cold medicine, also failed to detect the poison, officials
said.
The toxic pipeline ultimately emptied into the bloodstream of people
like Ernesto Osorio, a former high school teacher in Panama City. He
spent two months in the hospital after ingesting poison cough syrup
last September.
Just before Christmas, after a kidney dialysis treatment, Mr. Osorio
stood outside the city's big public hospital in a tear-splattered
shirt, describing what his life had become.
"I'm not an eighth of what I used to be," Mr. Osorio said, his
partly paralyzed face hanging like a slab of meat. "I have trouble
walking. Look at my face, look at my tears." The tears, he said
apologetically, were not from emotion, but from nerve damage.
And yet, Mr. Osorio knows he is one of the lucky victims.
"They didn't know how to keep the killer out of the medicine," he
said simply.
While the suffering in Panama was great, the potential profit � at
least for the Spanish trading company, Rasfer � was surprisingly
small. For the 46 barrels of glycerin, Rasfer paid Fortune Way
$9,900, then sold them to Medicom for $11,322, according to records.
Chinese authorities have not disclosed how much Fortune Way and the
Taixing Glycerine Factory made on their end, or how much they knew
about what was in the barrels.
"The fault has to be traced back to areas of production," said Dr.
Motta, the cardiologist in Panama who helped uncover the source of
the epidemic. "This was my plea � please, this thing is happening to
us, make sure whoever did this down the line is not doing it to Peru
or Sierra Leone or some other place."
A Counterfeiter's Confession
The power to prosecute the counterfeiters is now in the hands of the
Chinese.
Last spring, the government moved quickly against Mr. Wang, the
former tailor who poisoned Chinese residents.
The authorities caught up with him at a roadblock in Taizhou, a city
just north of Taixing, in chemical country. He was weak and sick,
and he had not eaten in two days. Inside his white sedan was a
bankbook and cash. He had fled without his wife and teenage son.
Chinese patients were dead, a political scandal was brewing and the
authorities wanted answers. Mr. Wang was taken to a hospital. Then,
in long sessions with investigators, he gave them what they wanted,
explaining his scheme, how he tested industrial syrup by drinking
it, how he decided to use diethylene glycol and how he conned
pharmaceutical companies into buying his syrup, according to a
government official who was present for his interrogation.
"He made a fortune, but none of it went to his family," said Wang
Xiaodong, a former village official who knows Mr. Wang and his
siblings. "He liked to gamble."
Mr. Wang remains in custody as the authorities decide whether he
should be put to death. The Qiqihar drug plant that made the
poisonous medicine has been closed, and five employees are now being
prosecuted for causing "a serious accident."
In contrast to the Wang Guiping investigation, Chinese authorities
have been tentative in acknowledging China's link to the Panama
tragedy, which involved a state-owned trading company. No one in
China has been charged with committing the fraud that ended up
killing so many in Panama.
Sun Jing, the pharmaceutical program officer for the World Health
Organization in Beijing, said the health agency sent a fax "to
remind the Chinese government that China should not be selling
poisonous products overseas." Ms. Sun said the agency did not
receive an official reply.
Last fall, at the request of the United States � Panama has no
diplomatic relations with China � the State Food and Drug
Administration of China investigated the Taixing Glycerine Factory
and Fortune Way.
The agency tested one batch of glycerin from the factory, and found
no glycerin, only diethylene glycol and two other substances, a drug
official said.
Since then, the Chinese drug administration has concluded that it
has no jurisdiction in the case because the factory is not certified
to make medicine.
The agency reached a similar conclusion about Fortune Way, saying
that as an exporter it was not engaged in the pharmaceutical
business.
"We did not find any evidence that either of these companies had
broken the law," said Yan Jiangying, a spokeswoman for the drug
administration. "So a criminal investigation was never opened."
A drug official said the investigation was subsequently handed off
to an agency that tests and certifies commercial products � the
General Administration of Quality Supervision, Inspection and
Quarantine.
But the agency acted surprised to learn that it was now in
charge. "What investigation?" asked Wang Jian, director of its
Taixing branch. "I'm not aware of any investigation involving a
glycerin factory."
Besides, Huang Tong, an investigator in that office, said, "We
rarely get involved in products that are sold for export."
Wan Qigang, the legal representative for the Taixing Glycerine
Factory, said in an interview late last year that the authorities
had not questioned him about the Panama poisoning, and that his
company made only industrial-grade glycerin.
"I can tell you for certain that we have no connection with Panama
or Spain," Mr. Wan said.
But in recent months, the Glycerine Factory has advertised 99.5
percent pure glycerin on the Internet.
Mr. Wan recently declined to answer any more questions. "If you come
here as a guest, I will welcome you," Mr. Wan said. "But if you come
again wanting to talk about this matter, I will make a telephone
call."
A local government official said Mr. Wan was told not to grant
interviews.
A five-minute walk away, another manufacturer, the Taixing White Oil
Factory, also advertises medical glycerin on the Internet, yet it,
too, has no authorization to make it. The company's Web site says
its products "have been exported to America, Australia and Italy."
Ding Xiang, who represents the White Oil Factory, denied that his
company made pharmaceutical-grade glycerin, but he said chemical
trading companies in Beijing often called, asking for it.
"They want us to mark the barrels glycerin," Mr. Ding said in late
December. "I tell them we cannot do that."
Mr. Ding said he stopped answering calls from Beijing. "If this
stuff is taken overseas and improperly used. ..." He did not
complete the thought.
In chemical country, product names are not always what they seem.
"The only two factories in Taixing that make glycerin don't even
make glycerin," said Jiang Peng, who oversees inspections and
investigations in the Taixing branch of the State Food and Drug
Administration. "It is a different product."
All in a Name
One lingering mystery involves the name of the product made by the
Taixing Glycerine Factory. The factory had called its syrup "TD"
glycerin. The letters TD were in virtually all the shipping
documents. What did TD mean?
Spanish medical authorities concluded that it stood for a
manufacturing process. Chinese inspectors thought it was the
manufacturer's secret formula.
But Yuan Kailin, a former salesman for the factory , said he knew
what the TD meant because a friend and former manager of the
factory, Ding Yuming, had once told him. TD stood for the Chinese
word "tidai" (pronounced tee-die), said Mr. Yuan, who left his job
in 1998 and still lives about a mile from the factory.
In Chinese, tidai means substitute. A clue that might have revealed
the poison, the counterfeit product, was hiding in plain sight.
It was in the product name.
Renwick McLean and Brent McDonald contributed reporting.

Haraq minge hejimini kichiklitiwitidu

HealthDay New yeni Saghlam Kuni Xewirining 5-ayning 2-kunidiki
xewiride bayan qilishiche haraq minge hejimini kichiklitiwitidiken.

Xewerde mundaq deyilgen, siz az miqdarda haraq ichkende belkim
yurekingizge bezi yardimi bolushi mumkin, biraq meyli siz az haraq
iching yaki kop haraq iching, u sizning mingizni kichiklitiwitidu
(shrink, 萎缩).

Amirkiliq tibi tetqiqatchi Carol Ann Paulning eytishiche, az
miqdarda haraq belkim yurekke paydisi bolushi mumkin, biraq haraq
istimal qilish bilen minge hejimi arisida menpi munasiwet bolup,
nahayti az haraq ichkendimu minge hejimige hichqandaq paydisi yoq.

Paulning bu baqishini, Amirka Nirva Kisellikler Jemiyiti (American
Academy of Neurology) ning Bostonda ichilghan yilliq yighinida ilan
qilghan.

Paul we uning xizmetdashliri 34 yashtin 88 yash ariliqidiki 1839
ademning minge MRI netijisige qarap chiqqan. Ular bu kishilerni
ezeldin haraq ichmeydighan, az haraq ichidighan (heptisige 1
romkidin 7 romka haraq ichidighan), ortahal haraq ichidighan
(heptisige 8 romkidin 14 romka haraq ichidighan), we kop haraq
ichidighan (heptisige 14 romkidin artuq haraq ichidighan) dep 4
gurpigha ayrip chiqqan. Netijide ular kop haraq ichidighanlarning
minge hejimi ezeldin haraq ichmeydighanlarning mingisige nisbeten
1.6% kichiklep ketkenligini bayqighan. Bu xil aqiwet haraq ichkuchi
ayallarda tiximu iniq bolidiken.

Hemmimizge melum bolghunidek ademning minge hejimi kichiklep ketse
yeni minge yigdep (脑萎缩) qalsa, iside saqlash we yingi nersilerni
ugunush qabiliyiti towenlep kitish, inkasi astilap kitish, qoli
titireydighan bolup qilish qatarlqi yaman aqiwetler kilip chiqidu
(buni men qoshumche qilip qoydum)

Bu xewer qisqartilip terjime qilindi, esli tikisini towendiki
ulanmidin korung.

http://www.nlm.nih.gov/medlineplus/news/fullstory_48723.html

Qarguni gin arqiliq dawalash

Towendiki xewerde eytilishiche Engiliyede qarghuni gen bilen
dawalash haywanda muhapiqiyetlik bolup, ademde sinaq qilish
basquchigha kirgen iken.

Qarghu bolsa hazirgha qeder saqaytish bek qiyin bolghan kisellerning
biri bolup, adem qarghu bolup qalghanda, gerche adem hayatigha
tehdit ekelmisimu, biraq turmush supiti eghir derijide towenley,
bimar bir omur qarangghuluq ichide yashashqa mejburu bolidu.
Qarghuni gin bilen dawalash kelguside kozi kormes bolup
qalghanlargha qaytidin umut nuri ata qilghusi.


UK doctors test gene therapy to treat blindness
Reuters Health

Tuesday, May 1, 2007

LONDON (Reuters) - A team of British doctors has carried out the
world's first eye operations using gene therapy to try to cure a
serious sight disorder, officials said on Tuesday.

The group from Moorfields Eye Hospital and University College London
(UCL) has operated on a small number of young adults with Leber's
congenital amaurosis, a type of inherited childhood blindness caused
by a single abnormal gene.

The condition prevents the retina from detecting light properly,
resulting in progressive deterioration and severely impaired
eyesight. There is no effective treatment.

The new experimental procedure involves inserting normal copies of
the faulty RPE65 gene into cells of the retina -- the light-
sensitive layer of cells at the back of the eye -- using a harmless
virus or vector.

The British doctors are working alongside Seattle, Washington-based
biotech firm Targeted Genetics Corp., which made the vector being
used in the Phase I/II trial.

It will be several months before the success of the procedure can be
properly assessed but medics said there had been no complications so
far.

The move into human testing follows 15 years of laboratory and
animal experimentation, including tests on dogs whose vision was
restored to the extent they could navigate a maze with ease.
"Testing it for the first time in patients is very important and
exciting and represents a huge step towards establishing gene
therapy for the treatment of many different eye conditions," Robin
Ali, professor of human molecular genetics at UCL, said in a
statement.

The clinical trial was given 1 million pounds ($2 million) of
funding by Britain's Department of Health, which said the pioneering
research underlined the country's leading position in gene therapy
in Europe.

The idea of using gene therapy to fix diseases caused by genetic
faults has long appealed to scientists, although getting the idea to
work in practice has proved tricky.

Some gene therapy approaches have helped patients. But one 18-year-
old volunteer died in a gene therapy experiment in 1999 and two
French boys cured of a rare immune disease later developed
leukaemia.

Over 70 percent of gene therapy trials to date have been for cancer,
where the process is complicated by the need to reach multiple sites
in the body.

The eye, by contrast, is relatively straightforward, said Andrew
George of London's Imperial College.

"The eye is good for gene therapy because it is a simple organ and
it is easy to see what is going on. There is hope that once gene
therapy is developed in the eye, scientists could move on to more
complex organs," he said.

Reuters Health

AIDS virusi bowaqlar qinida tiz yoshurnidu

Towendiki xewerde dokilat qilishiche AIDS ni dawalsh dorisigha
qarshi kuchi bar yeni dora tesir qilmaydighan AIDS virusi apidin
baligha yuqqandin kiyin, balining imiyunut sistimisidiki hujeyriler
ichige yoshurnup, bir nechche yilliq yoshurun mezgilni bishidin
otkuzidiken. Bu balilar arisidiki AIDS ni dawalashta alahide
tosqunluq rol oynaydiken.

Amirkida apisi AIDS virusi bilen yuqumlanghanlarning balisigha
yuqturush nisbiti texminen 25% bolsimu, biraq tereqqi qiliwatqan
dowletlerde bu nisbet xilila yuquri iken.

AIDS ni dawalsh dorisigha qarshi kuchi bar yeni dora tesir
qilmaydighan AIDS virusi dawalash eslidin qiyin bolghan AIDS
kisilini tiximu murekkepleshturmekte, AIDS ni dawalsh dorisigha
qarshi kuchi bar yeni dora tesir qilmaydighan AIDS virusi dawalash
eslidin qiyin bolghan AIDS kisilini tiximu murekkepleshturmekte, we
AIDS kisilige giriptar bolghan balilarning dawalash unimining towen
bolushigha sewep bolmaqta.

Memet Emin


AIDS virus hides quickly inside babies' blood

Reuters Health

Monday, April 30, 2007

WASHINGTON (Reuters) - Drug-resistant versions of the AIDS virus
passed from mother to child can quickly hide in the infant's immune
system cells and lurk for years, researchers reported on Monday.
This will limit what drugs the children can take to control their
infection, Dr. Deborah Persaud of Johns Hopkins University School of
Medicine in Baltimore and colleagues said.

While mother-to-child transmission of the AIDS virus has been slowed
in the United States by giving drugs to both the mother and the baby
at the time of birth, it is still a major cause of HIV infection in
the developing world.

If not treated, about 25 percent of newborns get the virus from
their infected mothers, either during birth or shortly after, while
breastfeeding.

Drug-resistant versions of the human immunodeficiency virus are also
a growing problem. People develop resistance while taking AIDS
drugs, but then this resistant virus can be passed from one person
to another.

Persaud's team studied 21 HIV-infected infants in 10 U.S. states.
They found five of them were infected with drug-resistant HIV from
their mothers.

The virus moved quickly to so-called resting or inactive CD4 T-
cells -- the cells normally infected by HIV, Persaud's team reported
in The Journal of Infectious Diseases.

The virus was resistant to a class of AIDS drugs called non-
nucleoside reverse transcriptase inhibitors or NNRTIs. But protease
inhibitors, another class of AIDS drugs, worked, the researchers
found.

"The initial transmitted drug-resistant virus will likely never be
cleared from that infant with currently available treatments,"
Persaud said in a statement.

The AIDS virus is especially difficult to fight because it infects
the immune system cells that usually battle a viral infection.
Single drugs do very little to control it, so it is important to use
cocktails of drugs that interfere with the virus at various points
in its life cycle.

There are currently about 20 different available AIDS drugs in
various classes, but patients with resistant virus automatically
cannot use several of them.

Reuters Health

AIDS dorisining hazirqi we kelgusi baziri

Towendiki xewerde eytilishiche AIDS ni dawalashta ishlitidighan
dorilarning sitilish qimmiti 2005-yili 7.1 miliyart (7.1 billion)
dollar bolup, 10 yildin kiyin yeni 2015-yiligha barghanda 10.5
miliyart dollar qimmitige yitidiken.

Hazir AIDS ni dawalashta ishlitidighan dorilarning mutleq kop qismi
nahayti qimmet bolup, adettiki kishilerning istimal sewiyesidin
xilila yuquri. Adettiki Uyghlargha nisbeten hazirche asasen mumkin
diyishke bolidu. Chunki bu dorilarni bir omur uzluksiz toxtatmay
ishlitip turush zorur.


AIDS Drugs Sales to Top $10 Billion by 2015

April 12, 2007

By Ben Hirschler

(Reuters Health) - The launch of new drugs and an increase in the
number of people diagnosed with HIV is set to make AIDS medicine a
$10.6 billion market by 2015, according to a report on Thursday.
Drugmakers may be under pressure to cut prices in the developing
world but selling HIV drugs in the West remains a lucrative and fast-
growing business.

Independent market research firm Datamonitor said the HIV/AIDS market
was set to undergo significant changes over the next 10 years as
drugs that work through novel mechanisms and next-generation versions
of existing drugs are launched.

Sales, as a result, should rise significantly from about $7.1 billion
in 2005, benefiting a clutch of companies with promising new
products, including Merck & Co Inc., Pfizer Inc., Gilead Sciences
Inc. and Johnson & Johnson.

Most cases of HIV/AIDS occur in sub-Saharan Africa, where lack of
funding means treatment is restricted and prices are under pressure,
resulting in little if any profit for multinational drug firms.

Just this week Abbott Laboratories Inc., widely criticised for
aggressive pricing of its AIDS medicines, agreed to slash the price
of its Kaletra AIDS drug by more than half in more than 40 poor
countries.

But at the same time the disease is also increasing in the developed
world, with an estimated 2.1 million people in North America and
Western Europe living with HIV in 2006, up from 1.9 million in 2004.

"Advances in antiretroviral therapy have turned HIV from a
universally feared death sentence into a chronic disease with an
average life expectancy similar to that of Type 2 diabetes,"
Datamonitor analyst Mansi Shah said.

"Because of this, attitudes towards HIV have become relatively blase
amongst some groups."

Notable new types of drugs include Pfizer's maraviroc, a CCR5
inhibitor, and Merck's raltegravir, an integrase inhibitor, which are
expected to be launched in 2007 and 2008 respectively.

They will complement new generation forms of existing drug classes,
such as Johnson & Johnson's recently approved Prezista, a protease
inhibitor.

Such products offer new treatment options for the growing number of
patients whose disease no longer responds to existing drugs.

At the same time, other companies are developing improved fixed-dose
drug combinations, including Atripla from Gilead, which combines the
components of current drug cocktails into a single pill that can be
taken once a day.

Atripla was launched in the United States last year and is expected
to take market share from its two components Truvada and Sustiva, as
well as competitor drugs such as GlaxoSmithKline Plc's Combivir,
Datamonitor said.

The global market for all pharmaceuticals grew 7 percent last year to
$643 billion, according to estimates from another market research
company, IMS Health, released last month.

Follow the simple diet tips from experts to get rid of those extra
pounds. Learn the most effective methods right here:
http://health.weightlossbud.com

Hazir Amirkida AIDS kisilini dawalashta ishlitishke testiqlanghan
dora turi jemi 22 xil bolup, bu dorilarning biri yaki ikki uchini
birleshturup ishlitip dawalash arqiliq, bimarning omurini uzartish
mexsitige yetkili bolidu. Eger kishiler AIDS virusi yeni HIV bilen
yuqumlunup qanche burun iniqlansa, we qanche burun dora ishlitip
dawalash ilip barsa, HIV yuqumlunushtin AIDS kisilige tereqqi qilish
suretini astilatqili bolushi mumkin. Yene usluksiz dawalash ilip
barsa, AIDS kisilining tereqqi qilishini astilatqili we bimarning
omurini uzartqili bolushi mumkin.

Amirkida Peter isimlik bir bimarning 1985-yili HIV bilen
yuqumlanghanlighi iniqlanghan iken. Eyni waqitta AIDS ni dawalashta
testiqlanghan dora asasen yoq ikenduq. 1987-yili AZT digen dora AIDS
kisilini dawalashta testiqliniptu. Shuningdin itiwaren bu kishi
uzluksiz dawalash ilip biriptu. Hazir 22 yildin kiyin bu kishi tixi
hayat iken.

Hazir bar bolghan yuqarqi 22 xil dora arqiliq dawalash ilip barghanda
qandiki HIV ni konturul qilip, kiselning tereqqi qilishini
astilatqili, we bimarning omurini uzartqili bolghan bilen, nahayti az
sandiki kishiler bedinidiki HIV ning yoqighanlighi toghursidiki
xewerlerni hisapqa almighanda muteleq kop sandiki kishilerning
bedinide HIV dawalamliq mewjut bolup turidu, we kopunche bimar AIDS
kisilige tereqqi qilghandin kiyin 5, 6 yil ichide olup kitidu. Shunga
hazirgha qeder AIDS kisili unumluk dawasi bolmighan kisel hisaplinip
kiliwatidu. Bundaq digenlik AIDS kisilige dawa yoq digenlik emes,
mundaqche eyitqanda AIDS kisilige dawa bar biraq unumluk dawa yoq.

Nurghun dawalash imkaniyiti tamamen bar bolghan kisellerge giriptar
bolghan Uyghurlar her xil sewepler tupeylidin unumluk dawalash
pursitige ige bolalmaywatqan bugunki kunde, "AIDS kisilige dawa
tipildi" digen xewerdin alahide hayajanlinip kitishning kop ehmiyiti
yoq. Eger AIDS kisilige unumluk dawa tipilghan bolsa, bu heqiqeten
bir xushallinarliq ish, biraq bizge nisbeten eng muhimi, AIDS ni
dawalash emes, belki uning aldini ilishqa tiximu ehmiyet birish. Eger
biz yiterlik ehmiyet bersekla, AIDS ksilining Uyghlar arisida
tarqilish suretini astilitalaymiz, we bara bara azlitalaymiz. AIDS
ning aldini ilish AIDS  kisilini dawalashqa nisbeten, Uyghurlargha
yiximu muhapiq, tiximu emili, tiximu ixtizadchil, tiximu yaxshi chare
hisaplansa kirek. Emiliyette kisel dawalashning ozi kiselning aldini
ilish meghlup bolghandin kiyin qollunidighan "amal yoqning amali".

Men burun dep otkendek AIDS kisili yolda kitiwatqan ademlerge
ozligidinla yuqup qalmaydu. Bir adem AIDS kisilige giriptar bolush
uchun, HIV bilen yuqumlunush kirek. HIV bilen yuqumlunushning asasliq
yolliri qalaymiqan jinsi munasiwet qilish, zeherlik chikimlikni
zeherlik chikimlik chekkuchiler arisida bir yingne bilen ortaq okul
qilip urush, andin qalsa qan silish, apidin baligha yuqush
qatarliqlar. Axirqi ikki sewepni hisapqa almighanda, AIDS bilen
yuqumlunushni asasen meyli dini itiqadimiz olchimi boyiche bolsun we
yaki hazirqi qanun tuzum olchimi bilen bolsun, "yaman ish qilish"
bilen munasiwetlik dep qarashqa bolidu. Elwette qan silish arqiliq
ozlirige AIDS ni yuqturiwalghan gunasiz kishilermu bar. Likin hazir
Uyghurlar arisidiki AIDS kisili bilen yuqumlanghanlarning omumi
yuzluk ehwalidin qarighanda, mutleq kop qismi yenila qalaymiqan jinsi
munasiwet qilish, zeherlik chikimlikni zeherlik chikimlik
chekkuchiler arisida bir yingne bilen ortaq okul qilip urush bilen
biwaste munasiwetlik. Shunga hayatimizni qedirleyli, ozimizge,
ahilimizge mesul bolayli. Ikkila alemde guna hisaplanghan ishlardin
qol uzeyli.

"Her qaysi d鰈etlerning t閘iwizur, radio, g閦it-jornallirida keng
k鰈emde teshwiq qilindi" digen bu xewerni men anglap baqmaptimen.
Shunga men buning hazirche iniq bir nerse diyelmeymen.

Shundaqtimu men oz koz qarashlirimni oturgha qoyap otmekchimen. Aldi
bilen "unumluk dawa" digen bu bir nisbi soz. Eger biz bu "unumluk
dawa" sozini mutlaq menesi bilen chushensek, hazir mewjut boliwatqan
kisellerning mutleq kop qismighan "unumluk dawa" yoq. Mesilen yurek
kisilige "unumluk dawa" yoq, yuquri qan bisimigha "unumluk dawa" yoq,
diyabit kisilige "unumluk dawa" yoq, rak kisilige "unumluk dawa"
yoq,  jigger yallughigha "unumluk dawa" yoq. "Unumluk dawa" tipilghan
kiseller asasen az. Chunki adem bu kisellerge giriptar bolghandin
kiyin, kopunchisini bir omur dawalap turush kirek, bolmisa yene qayta
qozghilidu. Eger biz bu "unumluk dawa" digen sozni nispi menide
ishletsek, yuqurdiki kisellerge hemmisige "unumluk dawa" bar. Hetta
Eydiz kisiligimu dora bar. Chunki yuqarqi kisellerge giriptar bolghan
kishiler eger uzluksiz dawalinip tursa kisel yaxshi konturul bolidu,
bimarning omurimu uziraydu. Mesilen yurek kisilige giriptar bolghan
bezi kishiler yaxshi dawalinish arqiliq, 20, 30 omur koreleydu. Biraq
beziler unumluk dawalashqa irishelmey tizla olup kitidu. Rak kisilige
giriptar bolghan kishilermu waxtida unumluk dawalansa 10 yildin artuq
omur koreleydu, eger waxtida unumluk dawlash ilip barmisa, belkim 1
yil ichide olup kitishi mumkin. Eydiz kisilige giriptar
bolghanlarning beziliri Amirkida 18 yildin artuq omur korgenler bar.

Shunga yuqarqi xewerde diyilgen dorining ras yalghanlighini peqet
waqit ispatlaydu. U dorining unimi bilen bir adem 10 yil artuq omur
korush uchun 10 yil waqit kirek.

Sumruq isimlik bir tordash, AIDS kisilini dawalash toghursida
towendiki xetni Biwal.com gha chaplighan iken

Hormetlik Doktor Memet Imin, yeqindin beri wetendiki tor betliride,
Eydiz kesilige dora tepildi degen yazma yamrap ketti. U keselge
raslam dawa tepilghan bolsa kishini hayajangha salmay qoymaydu. Siz
Eydiz kesili tughurluq kopligen maqalilerni yazghan idingiz. Shunga
sizning bu xewer tughurluq choqum xewiringiz bolishe mumkin. Mumkin
bolsa bu xewerning ras yaki yalghanliqi tughurluq melumat bergen
bolsingiz. Sizdin yene soal sorap aware qilidighanliqimdin epu
soraymen.

Salam bilen Sumruq

Dangliq islam dewetchisi, qur'an we hedistiki ilmi m鰆ize tetqiqat
hey'itining qurghuchisi, iman unw閞sit閠ining reisi yemenlik
proffisor sheyx abdulmejid ez-zindani, y閝inda 鰖ining y閠ekchiligi
astidiki t閎bi tetqiqat guruppisining hazirghiche dorisi t閜ilmighan
k閟el eydizgha dora keshp qilghanlighini 閘an qildi. Bu xewer
y閝indin b閞i p黷黱 xelqara axbarat sahesining diqqitini jelp qilip,
p黷黱 dunyani zil-zilige kelt黵di. Her qaysi d鰈etlerning t閘iwizur,
radio, g閦it-jornallirida keng k鰈emde teshwiq qilindi. Proffisor
sheyx abdulmejid ez-zindanining 閥tishiche, b黦黱ki bu netije 15
yilliq tetqiqat we izdinishning m閣isi bolup, peyghember
eleyh閟alamning 玝ir k閟elni ch黶h黵gen iken uning dawasinimu birge
ch黶h黵idu, uni bileligenler bilidu, bilelmigenler bilelmeydu� d間en
hedisige asasen, choqum bu k閟elningmu dorisi barghu d間en izg�-黰黷
bilen tetqiqatni bashlighan iken. Keshp qilin'ghan dorining terkiwi
qismi toghruluq qisqiche ch黶henche b閞ip, buningda ishlitilgen
dorilar peyghember eleyh閟salamning hedisliride tilgha 閘in'ghan bir
qisim tibbi 鰏黰l黭 we bashqa eshyalardin terkip tapqan bolup,
xelqara dora ishlesh 鰈chimi we qanun pirinsiplirigha tamamen riaye
qilin'ghan , emma keshp qilin'ghan dorining pat閚t hoquqi t閤i qanuni
jehettin kapaetlendurulmigechke bu heqte artuq melumat
b閞ilmeydighanliqini eskertti we dunyadiki barche dora ishlesh
shirketliri we b.D.T gha qarashliq sehiye ishliri teshkilati dorini
k鰖din kech黵黶h we bu dora bilen dawalan'ghan kishilerning
xelqaradiki eng ilghar labiraturiyelerde 閘ip b閞ilghan,
dawalan'ghandin k閥inki teksh黵黶h netijisini k鰎黶h 點h黱 yemenni
ziyaret qilishqa chaqirdi. Igellinishiche, bu dora bilen
dawalan'ghandin k閥in eydis w閞usidin telt鰇黶 qutulup, saghlamlighi
eslige halitige qaytqanlar 20 kishige yetken. Shundaqla bu dorining
yene (B,C ) tipliq yuqumluq jiger k閟ellikliri we shiker k閟ilini
dawalashta alahide 黱黰 bergenligi ispatlan'ghan. Hazirghiche bu
xildiki k閟ellerni dawalash musulman yaki kapir bolushigha qarimastin
heqsiz 閘ip b閞ilmaqta. Islamgha her xil t鰄metlet toqiliwatqan,
muhemmet eleyh閟salamgha her t黵l黭 hujumlar qiliniwatqan mushundaq
jiddi bir peytte, xelqarada radikalliq we t閞orchiliq bilen eyiplinip
b.D.T ning qara tizimlikige kirg鼁黮gen bir sheyix teripidin, 鰈黰
girdaw閐a ejilini k黷黽atqan milyunlarche insan'gha shipa
b間hushlighuchi bir dorining ijat qilinishi islam dinining heqiqeten
barche insaniyetke rehmet, mihri-shepqet b間hishlughuchi bir din
ikenligini, musulmanlarning insaniyetke neqeder k鰕黰chan kishiler
ikenligini dunyagha yene bir jakarlidi.

Menbe:anayurt munbiri

Vitamin K we qan tomur qetish

Doxtur Memetiminning  Shair Batur Rozining oelimi
munasiwiti bilen yazghan "Uyghurlardiki yurek
kisilining ushtumtut qozghilishi tupeylidin qaza
tepishini Uyghurlarning yimeck ichmek, turmush aditi
bilen baghlighanliqini ispatlighan bir tetqiqat iken.
Qizil qan tomurni tazilashqa yardimi bolidighan
Vitamin K koep bolidighan yemeklikler soybean, olive
and canola oils, and dark green vegetables such as
broccoli, kale, spinach and Brussels sprouts
qatarliqlar iken.
Lekin men ularning kopining ismini  Uyghur elidiki
chaghlarda anglapmu baqmighan ikenmen. Qarighanda
Uyghurlarning yimek ichmek aditi bilen qan tomur
keselliklirining munasiweti zich oxshaydu.



***********************************
Vitamin K May Help Clear Arteries

MONDAY, April 2 (HealthDay News) -- Animals given high
levels of vitamin K showed a 37 percent reduction in
calcium buildup in their arteries, a new study finds.

Arterial calcification is an independent risk factor
for cardiovascular disease, researchers noted.

The Dutch study, by researchers at Maastricht
University, is the first in animals to show that
arterial calcification and resulting decreased
arterial elasticity can be reversed by consuming high
levels of vitamin K. The findings support the results
of a Rotterdam population-based study published in
2004.

This research into the benefits of high vitamin K
intake may prove especially important for people
taking blood thinning medications, such as warfarin,
which are known to cause rapid calcification in the
arteries. Many patients taking blood thinners aren't
aware of this risk, the researchers said.

Vitamin K is found in many kinds of foods, including
soybean, olive and canola oils, and dark green
vegetables such as broccoli, kale, spinach and
Brussels sprouts. Vitamin K is also available in
supplements.

The study was funded by Maastricht University and is
published in the April 1 issue of the journal Blood.
**********************





________________________________________________________________________________\
____
No need to miss a message. Get email on-the-go
with Yahoo! Mail for Mobile. Get started.
http://mobile.yahoo.com/mail

Passip tamaka chikishi we balilar tebirkiloz kisili

Towendiki xewerde bayan qilishiche tebirkiloz kisilige giriptar
bolghanlar mewjut sharahitta chonglar checkken tamaka shu muhittiki
balilarning tebirkiloz kisilige giriptar bolush xetirini ashuridiken.
Uyghurlar arisida her xil tebirkiloz kisilige giriptar bolghanlar
nahayti kop bolup, xili kop sandiki bimarlarda alahide kisellik
alamiti bolmighachqa ozining tebirkilozgha giriptar bolghanlighini
bilmeydu. Hem shundaqla Uyghurlar arisida kichik bala bar oydimu
tamaka chikidighan ehwal yenila mewjut bolup, meyli adettiki
olturash, toy tukun we her xil sorunlarda bu xil ehwal tiximu omum
yuzluk mewjut. Miningche biz balilarni kelgusining egiliri
deydikenmiz, ularning saghlam osup yitilishige toluq shert sharahit
yitildurshimiz kirek. Ozingiz we bashqilarning salametligi uchun
bolsimu oy ichide we ammawi sorunlarda tamaka chekmeng.

Passive smoking linked with TB risk in children

Thursday, April 5, 2007

NEW YORK (Reuters Health) - A study conducted in South Africa
suggests there is an association between passive smoking and
increased risk of Mycobacterium tuberculosis infection in children
living in a home with a tuberculosis patient.

"Tuberculosis and smoking are both significant public health
problems," Dr. Saskia den Boon, of KNCV Tuberculosis Foundation, The
Hague, Netherlands, and colleagues write in the April issue of
Pediatrics. The possible association between passive smoking and TB
infection in children "is a cause of great concern, considering the
high prevalence of smoking and tuberculosis in most developing
countries."

The team conducted a community survey that included 15 percent of the
addresses in two adjacent low- to middle-income suburbs in Cape Town.
All children younger than 15 years of age and their adult household
members living at the addresses were included in the study.

All of the children received a tuberculin skin test, with M.
tuberculosis infection defined as a reaction of at least 10 mm. The
team defined passive smoking as living in a home with at least one
adult who smoked for at least 1 year.

A total of 1344 children were included in the analysis. Of these, 432
(32 percent) had a positive tuberculin skin test and 1170 (87
percent) were classified as passive smokers.

The rate of positive tuberculin skin tests was 34 percent in children
with a smoker in the home compared with 21 percent in those who were
not passive smokers. The difference was not statistically significant.
However, there was a significant association between passive smoking
and a positive tuberculin skin test in the 172 households that had
with a patient with tuberculosis. Children living in these conditions
were nearly five-times as likely to test positive.

"Passive smoking might affect the immune system of the child, thus
increasing the risk of getting infected," den Boon and colleagues
suggest. Tobacco smoke exposure alters cell function, such as
lowering the rate of clearance of inhaled substances and abnormal
permeability of cells and blood vessels.

The investigators note that "in many developing countries with a high
burden of tuberculosis, the prevalence of smoking is rapidly
increasing, especially among women." The proportion of women who
smoke is particularly worrisome, they add, "because they expose their
children to tobacco smoke."

SOURCE: Pediatrics, April 2007.

Yurek kisilining ushtumtut qozghilishi
(Heart Attack)

Memet Emin

Yurek kisilining ushtumtut qozghilishi (heart attack, 心脏病突发)
diginimiz tajisiman yurek qan tomur kisili (coronary artery disease,
冠心病) ning ushtumtut qozghulishi bolup, adette yurekni qan bilen
teminleydighan tajisiman qizil qan tomuri (coronary artery, 冠状动脉)
ning bezi tarmiqi ushtumtut tosulup qilish we yurekke qan
yitishmeslik netijiside peyde bolghan kisellikni kozde tutidu.

Yurekni qan bilen teminleydighan tajisiman qizil qan tomurining melum
tarmiqi ushtumtut tariwilish we yaki tosulup qilish bilen yurek
muskulliri (heart muscle, myocardium, 心肌) melum dahirde
qansizlinip, yiterlik oksigingha irishelmeydu, netijide sol kokrigi
yaki kokrek songikining sol teripi aghirish, terlesh, kongli ilishish
yaki yandurghusi kilish, put qoli maghdursizlinish, dimi siqilish
yaki nepes qiyinlishishtek alametler kilip chiqidu. Bu yurek
kisilining ushtumtut qozghilishining tipik alametliri bolup
hisaplinidu. Qan tomurning ushtumtut tosulup qilishini kopunchi
hallarda uyshiwalghan qan (blood clot, 血凝块) kelturup chiqiridu.
Eger yurek muskullirigha qan yitishmeslik ehwali melum waqit ichide
unumluk bir terep qilinmisa, bir qisim yurek muskulliri olushke
(myocardial infarction, 心肌梗死) bashlaydu, shuning bilen tiximu
yaman aqiwet kilip chiqishi, eghir bolghan bimar ushtumtut olup
kitishi mumkin.

Tajisiman yurek qan tomur kisilining ushtumtut qozghulushi nahayti
tiz bolsimu, biraq bu xil kisel emiliyette bir nechche yilda asta
asta peyda bolidu. Qandiki ihtiyajdin artuq kolestirol (cholesterol,
胆固醇) we maylar (fatty substances, 脂肪) asta asta qan tomur timigha
olturushup,  qan tomur qitishidu, qan tomurning ilastikiliqi
towenleydu, shundaqla qan tomur taridu, netijide tajisiman yurek qan
tomur kisili kilip chiqidu.

Tajisiman yurek kisilining ushtumtut qozghilishi yurek sanjiqi
(angina, 心绞痛) bilen bashlinidighan bolup, yurek sanjiqi adette bir
nechche minuttin bir nechche saet dawam qilidu. Tajisiman yurek
kisilining ushtumtut qozghilishini bir terep qilishning eng yahshi
usuli waxtida dohturgha korunup, waxtida dawalash ilip birish.
Tajisiman yurek kisili ushtumtut qozghalghanda, eger tiz bir terep
qilinsa, aqiwiti (outcomes, prognosis预后) yaxshi bolidu. Mesilen
yurek sanjiqi (angina, 心绞痛) qozghalghandin kiyin derhal dawalash
ilip birip, uyushup qalghan qanni iritidighan, tariwalghan qan
tomurni kengeytidighan dora ishletse, qan tomurning ushtumtut tosulap
qilishini kelturup chiqarghan qan uyushmiliri irip, yurekni qan bilen
teminleydighan qan tomur qaytidin ichilip we kengiyip, yurekning qan
teminati eslige kilishi, yurek muskullirining mengguluk olushining
aldini alghili bolushi yaki olush dahirsini kichikletkili bolushi,
shuning bilen yaman aqiwetlerdin saqlanghili bolushi mumkin.

Tajisiman yurek qan tomur kisili (coronary artery disease, 冠心病) ni
peyda qilidighan yuquri kolestirol (cholesterol, 胆固醇) we yuquri
qan bisimi (high blood pressure, 高血压) qatarliq xeterlik amillarni
towenlitish arqiliq, Yurek kisilining ushtumtut qozghulushi yaki
qayta qozghulushning aldini alghili bolidu.

Yurek we yurek kisilige munasiwetlik sanliq melumatlar

1. Balaghetke yetken kishining yuriki oz mushte bilen teng
chongluqta bolidu.
2. Yurek adette tohtimastin 100 yildin artuq hizmet qilalaydu.
3. Yurek minutigha tehminen 60 qitim, saetige 3600 qitim, kunige
86400 qitim, yiligha 31.5 milyun qitim soqudu.
4. Yurek bir omurde 2.4 miliyart qitim soqup, 1 miliyun chilek
qanni yurektin bedenning herqaysi qismigha yetkuzup biridu.
5. Amirkida tehminen 26.3 miliyun er, 22.7 miliyun ayal, tama
chikish sewibidin Yurek kisilining ushtumtut qozghilishige giriptar
bolush girdawigha mangidu.
6. Qandiki kolestirolning yuquri towen bolushi, Yurek kisilining
ushtumtut qozghilishige giriptar bolush hetirining yuquri towen
bolushigha baha biridighan yahshi olchem.
7. Tehmine 99.5 miliyun balaghetke yetken Amirkiliqning qandiki
omumi kolestiroli 200 mg/dl gha yetken yaki uningdin ashqan, tehminen
39.9 million balaghetke yetken Amirkiliqning qandiki omumi
kolestiroli 240mg/dl gha yetken yaki uningdin ashqan.
8. 50 miliyun Amirkiliqning qan bisimi yuquri bolup, bu
Amirkiliqlarning Yurek kisilining ushtumtut qozghilishige giriptar
bolush hetirini ashuridu.
9. Tehmine her 29 sikunutta bir Amirkiliqning yurek kisili
qozghulidu.
10. Tehminen 7.2 miliyun 20 yash we uningdin chong Amirkiliq
Yurek kisilining ushtumtut qozghilishini bashtin kechurgen. Bularning
ichide 4.4 miliyuni er, 2.8 miliyuni ayal.
11. Her yilda tehminen 1.1 miliyun Amirkiliq yingidin Yurek
kisilining ushtumtut qozghilishi giriptar bolidu.

Yurekning normal yurek qurulmisi we xizmet ehwali.
.
Balaghetke yetken kishining yurikining chongliqi adette oz mushti
bilen teng bolup, kokrek qismining sol teripige jaylashqan. Yurekning
ichide 4 boshluq bolup, ikkisi ong we sol qirincha (left and right
ventricle, 左右心室), qalghan ikkisi ong sol dalancha (left and right
atrium, 左右心房) dep atilidu. Ular ayrim ayrim halda bedenning
herqaysi jayliridin qaytip kelgen oksiginsiz qanni yurekke yighip,
andin opkige yollash, we shundaqla opkidin kelgen oksiginliq qanni
yurekke toplap andin bedenning herqaysi jaylirighan yetkuzup birish
hizmitini oteydu. Bular beden qan aylinish we opke qan aylinish dep
atilidu.

Yurek ozidiki qandin biwaste oksigin we ozuqluqqa irishelmeydu. Yurek
kireklik bolghan oksigin we ozuqluqqa, yurekni qan bilen
teminleydighan tajisiman qan tomur arqiliq ige bolidu. Tajisiman qan
tomuri beden qan aylinish sistimisining bir qismi bolup, ong sol ikki
tajisiman qizilqan tomuri (coronary artery, 冠状动脉) we ong sol ikki
tajisiman kok qan tomuridin (coronary vein, 冠状静脉) ibaret 4 chong
qan tomur, nurghun kichik qan tomur we qildam qan tomurlardin terkip
tapqan.

Yurek tajisiman qizil qan tomur kisili we uning ushtumtut
qozghilishidiki sewebler we xeterlik amillar

Qandiki kolestirol we mayning miqdari ihtiyajdin iship ketkende,
artuq kolestirol we maylar qan tomur timigha olturshidu, shuning
bilen qan tomurni qitishidu we qan tomurning ilastikiliqi towenleydu,
bu qan tomurning qitiwilishi (atherosclerosis, 动脉硬化症) dep
atilidu. Qan timigha olturushup qalghan kolestirol we maylar teng
waqitta qan tomurni taraytiwitidu, qan tomurdiki qan iqimi astiliaydu
we azidu, shundaqla qan tomurning asan tosuluq qilishini kelturup
chiqiridu, netijide yurekni qan bilen teminleydighan qan tomurdiki
qan iqimi putunley tohtap qalidu, shuning bilen yurekke qan we
oksigin yitizmeslik kilip chiqidu.

Towendiki amillar kishilerning tajisiman yurek qan tomur kisilige
giriptar bolush ihtimalliqini ashurwitidu.

1. Irsiyet. Bezi kishilerning bu kiselge giriptar bolush nisbiti
bashqilardin yuquri bolidu. Yeni ata anisida yurek kisili bar bolsa,
ballirining bu hil kiselge giriptar bolush nisbiti yuquri bolidu.
2. Yash. Bu kiselge giriptar bolghuchilarning kopunchisi 40
yashtin yuqurlar bolup, yashning chongiyishigha egiship, kishilerning
bu kiselge giriptar bolush nisbiti yuqurlap baridu. 20 yashtin
towendiki kishilerde yaki kichik balilar bu kiselge giriptar bolmaydu.
3. Simizlik we beden ighirliqi. Simiz we beden ighirliqi
heddidin ziyade yuquri bolghan kishilerning bu hil kiselge giriptar
bolush nisbiti yuquri bolidu.
4. Tamaka chikish. Tamaka chekkuchilerning bu hil kiselge
giriptar bolush nisbiti yuquri bolidu.
5. Yimeklik aditi. Kop miqdarda gosh we may bolupmu
haywanlarning toyunghan miyini kop istimal qilghan kishilerning bu
kiselge giriptar bolush nisbiti yuquri bolidu.
6. Qan bisimi yuquri bolghan kishilerning bu kiselge giriptar
bolush nisbiti yuquri bolidu.
7. Herkiti we beden chiniqturushi kem bolghan kishilerning bu
kiselge giriptar bolush nisbiti yuquri bolidu.
8. Rohi jehettiki bisim, kongel aghriqi, turmush we xizmettiki
bisim we jiddichiligi, heddidin ziyade charchap kitish we harghinliq,
bu kiselning qozghulishi we tereqqi qilishigha sewepchi bolidighan
asaliq amillar hisaplinidu.

Yurek tajisiman qizil qan tomur kisilide we u ushtumtut qozghalghanda
qandaq alametler bolidu?

1. Yurek sanjiqi (angina, 心绞痛) Yurek kisilining ushtumtut
qozghilishining eng deslepki we eng kop uchuraydighan alimiti bolup,
kokrek songikining sol teripi aghrish yaki yurek mojulush, aghiriq
kokrektin sol ghejgisige we dolisigha kengiyishtek alametlerni
korsitidu. Bu alametler asasliqi yurekke waqitliq qan yitishmeslik
tupeylidin kilip chiqidu. Bu bimarning Yurek kisilining ushtumtut
qozghilishige giriptar boliwatqanlighidin yaki bu kiselning
qozghulush aldida turiwatqanlighidin direk biridu.
2. Sol kokriki qattiq aghrish. Bu xil aghriq asasen yurek
muskulliri qansizlinip olushke bashlighanliqtin kilip chiqqan.
3. Dimi siqilish we nepisi qisilish yaki qiyinlishish.
4. Bedendin soghaq ter chiqish.
5. Put qoli maghdursizlinip yiqilip chushush we ornidin
turalmasliq, hetta hushidin kitish.

Yurek tajisiman qizil qan tomur kisili we uning ushtumtut
qozghilishigha qandaq diyagunuz qoyulidu?

Towendikilerge asaslinip yurek kisilining ushtumtut qozghilishigha
yaki yurek tajisiman qizil qan tomur kisilige diyagunuz qoyush mumkin.
1. Yuqarda diyilgen yurek sanjiqi, nepisi qisilish, dimi
siqilish, terlesh we put qoli maghdursizlinish qatarliq tipik
alametler. Biraq bu alametlerning besiliri ashqazan yarisi, yurek
tashqi perde yallughi (Pericarditis, 心包炎), yurek muskul yallughi
(Myocarditis,  心肌炎, kokrek perde yallughi, kokrek boshlughuda su
bolush, we yaki kokrek perdisi chapliship qilish qatarliq
kisellerdimu korulidighan bolghachqa, bu kiseller bilen
periqlendurushke diqet qilish kirek.
2. Yurek soqush dolqunlirini eliktirliq zatirlesh
(electrocardiogram, ECG, 心电图). Yurek sanjiqi qozghalghan haman,
derhal yurek dolqunlirini eliktirliq zatirligende, bezi normal
bolmighan yurek soqush dolqunlirini zatirliwilish mumkin. Buningha
asasen bu aghriqning yurek kisili kelturup chiqarghan yaki
chiqarmighanlighigha hokum qilghili bolidu. Biraq tekshurush
netijsining normal bolushi, bu kishide u kiselning yoqluqidin direk
bermeydu. Bu xil ehwal astida eng yaxshisi yurek soqush dolqunlirini
24 saet uzluksiz xatirlesh kirek, yaki kiyin yurek sanjiqi
qozghalghanda, eng qisqa waqit ichide doxturgha birip, derhal yurek
dolqunlirini eliktirliq xatirlesh kirek.
3. Qan tekshurush. Qan tekshurush arqiliq qandiki kolestirolning
miqadirigha, yurekning zehmilinish ehwaligha we munasiwetlik
melumatlargha ige bolush mumkin.
4. Kokrekni rintigin resimige ilish (Chest SH-ray). Kokrek
rintigin resim arqiliq yurek, opke we qowurghuning ehwalini bilish
mumkin.
5. Yuquri chastotiliq awaz dolqunliri arqiliq yurek soqush
dolqunlirini hatirlesh (Echocardiography, 超声波心动描记法). Bu hil
tekshurush arqiliq yurekning qurulmisi, yurekning hizmet ehwali,
yurektin iqip chiqqan qan iqimi qatarliq ehwallargha ige bolush
mumkin.
6. Yurekning herketke berdashliq birish ehwalini tekshurush
(Eshercise Tolerance Or Stress Test, 运动耐量试验). Bu tekshurush
arqiliq yurek soqushidiki ber normalsiz dolqunlarni qozghap, yurek
soqush dolqunlirini eliktirliq hatirlesh usuli arqiliq bu normalsiz
dolqunlarni hatirligili bolidu, we shu arqiliq yurek kisilige
diyagunuz qoyush mumkin.
7. Radiyaktipliq resim (Nuclear Imaging) ilish. Bu tekshurush
arqiliq yurek muskullirining qan bilen teminlinish (myocardial
perfusion) yaki qansizlinish (myocardial ischemia) ehwaligha ige
bolghuli bolidu.
8. Undin bashqa yurek qan tomurigha neyche silish (Cardiac
Catheterization, 心导管插入术) we tajisiman qan tomurigha rintigin
resimige iniq chiqidighan dora urup tekshurush (Coronary Angiography,
冠状血管造影术) qatarliq tekshurushlerni ilip birish kirek.

Yurek tajisiman qizil qan tomur kisili we uning ushtumtut
qozghilishining aldini ilish

Yurek tajisiman qan tomur kisilini we uning ushtumtut qozghilishning
aldini ilish uchun towendikilerge diqet qilish kirek.

1. Yimeklik aditini ozgertish, towen mayliq, towen
kolestirolluq, towen shikerlik, yuquri aqsilliq yimekliklerni istimal
qilish, gosh maylarni az istimal qilish, koktatlarni we osumluk
yimekliklirini kop istimal qilish kirek.
2. Ighirliqini konturul qilish, muhapiq beden chinuqturup birish
kirek.
3. Tamaka chekmeslik, eger tamaka chikip adetlengen bolsa amal
bar tamakini tashlash kirek.
4. Qan bisimini yaxshi konturul qilish kirek, eger qan bisimi
yuquri bolsa waxtida dora yep, normal dahirde konturul qilish kirek.
5.  Rohi jehette bek jiddileshmeslik, alhide charchap ketmeslik,
xizmet, beden chiniqturush we aram ilishni muhapiq ilip birish kirek.
Birer ishqa bek qayghurup we achchiqlinip ketmeslik, keypiyatini
yaxshi tutush kirek.
6. Yurek kisilige diyagunuz qoyulghandin kiyin, waxtida dora
yep, munasiwetlik alametlerni yaxshi konturul qilish, yurek
sanjiqining qayta qayta qozghulup, yaman aqiwet ilip kilishning
aldini ilish kirek.

Batur Rozining Ushtumtut Qaza tipishi munasiwiti bilen

Memet Emin

Hemmimizge melum bolghunidek 2007-yili 3-ayning 27-kuni el soygen
ataqliq yazghuchi, shahir we terjimanimiz Batur Rozi yurek kisili
ushtumtut qozghulush sewibi bilen bizdin waqitsiz ayrildi. Emdila 40
yashqa kirgen bu oghlanimizning olimi weten ichi we sirtidiki
xelqimizni choqur qayghurgha chomdurdi, we shundaqla xelqimiz
arisida “nime uchun kozge korungen ziyalilirimiz we zatlirimizning
omuri kunsayin qisqa bolidu”digen sual we tuyghularni peyda qildi.

Anglashlargha qarighanda merhum Batur Rozining yoshurun yurek kisili
yeni tajisiman yurek qan tomur kisili bolup, 3-ayning 27-kuni kochida
kitiwatqanda yurek kisili ushtumtut qozghulup, yiqilip chushup
kochida yirim saetlerche yitip qalghan. Eyni waqitcha kochida shunche
kop ademler bolghan bolsimu, biraq kopunche kishilerning kari
bolmighan, kiyin yaxshi kongel birsining jiddi qutquzushqa xewer
qilish bilen, jiddi qutquzush mashinisi kilip, bimarni doxturxanigha
ilip barghan, biraq qutquzush unum bermey, xelqimizdin waqitsiz
ayrilghan (merhumning yatqan yiri jennet bolsun).

Yurek kisili yeni tajisiman yurek qan tomur kisilining ushtumtut
qozghilishi diginimiz adette yurekni qan bilen teminleydighan
tajisiman qizil qan tomurining tariwilishi we ushtumtut tosulup
qilishi sewibidin yurekke qan yitishmeslik netijiside peyde bolghan
kisellikni kozde tutidu.

Tajisiman Yurek Qan Tomur Kisili (冠心病), Yuquri Qan Bisimi (高血压),
Qizil Qan Tomur Qitiwilish Kisili (动脉硬化), Minge Qansizlinip Olush
Kisili (脑梗死), Mingige Qan Chushush Kisili (脑出血), Minge Qan
Tomuri Qitishiwilish Kisili (脑血管硬化) we diaybit kisili (糖尿病)
qatarliq kiseller adette ixtizadi tereqqi qilghan rayon, dowletlerde
we yaki ixtizadi yaxshi kishiler arisida kop uchuraydighan
bolghachqa, beziler bu kisellerni “baylar kisili”dep atishidighan
bolup, bu kiseller asasen kishilerning gosh, may we tatliq yimeklik
qatarliq yuquri inirgiyelik yimekliklerni kop istimal qilishi bilen
biwaste munasiwetlik bolup, herketni az qilidighan simiz kishiler
arisida kop uchuraydu. Bu kiseller adette ixtizadi tereqqi qilmighan
kembighel rayunlardiki kembighel kishiler arisida bek kop uchurmaydu.

Amirkida her yili 1.5 miliyun kishining yurek kisili ushtumtut
qozghulidighan bolup, yurek kisili Amirkida birinji derijilik chong
qatil hisaplinidu. Biraq Amirkida yurek kisilining ushtumtut
qozghulushi sewibi bilen olup kitiwatqanlarning kopunchisining yishi
asasen 60~70 yashtin yuquri bolup, mutleq kop qisim kishiler yurek
kisilige giriptar bolghandin kiyin 20~30 yil omur koreleydu.

Uyghur ili gerche ixtizadi anche tereqqi qilmighan rayon
hisaplansimu, biraq bu kiselge giriptar bolush nisbiti nisbeten
yuquri bolghan rayunlarning biri bolup, her yili kopligen Uyghurlar
yurek kisilining ushtumtut qozghilishi tupeylidin qaza tapidu. Mutleq
kop qismi 50 yash etirapida bolup, yiqinqi yillardin buyan yurek
kisilining ushtumtut qozghulishi tupeylidin olup kitiwatqan Uyghurlar
bolupmu ziyalilar yildin yilgha yashliship barmaqta. Bu asasen
Uyghurlarning yimeck ichmek, turmush aditi we Uyghurlar yuzliniwatqan
ijtimayi mesililer bilen biwaste munasiwetlik bolup, her birimizning
oylunishigha we kongel bolushige erzidu.

Towende men bashqilarning paydilishi uchun, tajisiman yurek kisili we
uning ushtumtut qozghulishi toghursida bilgenlirimni oturgha qoyap
otmekchimen.

Baylar Kisili we Kembigheller Kisili

Memet Emin

Baylar kisili digen qandaq kisel?

Bezi kishiler ixtizadi tereqqi qilghan rayon, dowletlerde we yaki
ixtizadi yaxshi kishiler arisida kop uchuraydighan bezi kisellerni
baylar kisili dep ataydighan bolup, bu kiseller Tajisiman Yurek Qan
Tomur Kisili (冠心病), Yuquri Qan Bisimi (高血压), Qizil Qan Tomur
Qitiwilish Kisili (动脉硬化) qatarliq yurek qan tomur kisili (心血管疾
病), Minge Qansizlinip Olush Kisili (脑梗死), Mingige Qan Chushush
Kisili (脑出血), Minge Qan Tomuri Qitishiwilish Kisili (脑血管硬化)
qatarliq minge qan tomur kisili (脑血管疾病) we diaybit kisili (糖尿病)
qatarliq kisellerni oz ichige alidighan bolup, bu kiseller asasen
kishilerning gosh, may we tatliq yimeklikler qatarliq yuquri
inirgiyelik yimekliklerni kop istimal qilishi bilen biwaste
munasiwetlik bolup, herketni az qilidighan simiz kishiler arisida kop
uchuraydu. Bu kisel adette ixtizadi tereqqi qilmighan kembighel
rayunlardiki kembighel kishiler arisida bek kop uchurmaydu.

Shuni eskertip otushke erziduki, ixtizadi tereqqi qilghan
dowletlerdiki heqiqi bay kishiler we mediniyet sewiyesi yuquri
kishiler gosh mayni we tatliq yimekliklerni kop istimal qilishning
ziyinini tonup yetkenligi, yimek ichmekte ozini qattiq konturul
qilidighanlighi we beden chiniqturushqa alahide ehmiyet birishke
adetlengenligi uchun, hazir bu atalmish “baylar kisili” heqiqi bay
kishiler arisida kunsayin azlap, tereqqi qilghan memliketlerdiki
kembigheller arisidila kop uchuraydighan bolup qaldi. Eger siz
Amirkida alahide simiz ademni uchuratsingiz, siz u kishini ixtizadi
kirimi we medinyet sewiyesi anche yuquri emes, we yaki hokumettin
qutquzush puli ilip, baker yep baker ichidigha kishi dep perez
qilsingiz, perizingizning toghura bolush ixtimalliqi 90% din artuq
bolidu.

Kembigheller kisili digen qandaq kisel?

Bezi kishiler ixtizadi tereqqi qilmighan rayon, dowletlerde we yaki
kembighel kishiler arisida kop uchuraydighan bezi kisellerni
kembigheller kisili dep ataydighan bolup, bu kiseller her xil
tebirkiloz kisili (结核病), jigger yallughi (肝炎), bezgek (疟疾),
kezik (伤寒), ichi suruk (痢疾)，qapliq qurut kisili (包虫病), her xil
medde qurut kisili (寄生虫病) qartarlqi her xil yuqumluq kisellerni oz
ichige alidighan bolup, bu kiseller asasen kishilerning yimek
ichmeklirining nachar bolushi, yeni ozuqluq yitishmeslik, yimek
ichmek tazliqining nachar bolushi, kishilerning tazliq we ang
sewiyesining towen bolushi qatarliq sewepler bilen biwaste
munasiwetlik. Bu kiseller adette Afriqining otur qismidiki tereqqi
tapmighan dowletler bilen bezi Asiya dowletliride kop uchuraydu,
biraq tereqqi qilghan gherip memliketlerde we ixtizadi yaxshi bolghan
bay kishiler arisida asasen bek kop uchurmaydu.

Uyghur ili adette ixtizadi tereqqi qilmighan rayon hisaplinidighan
bolup, yuqurda dep otken “embigheller kisili” kop uchurghandin
bashqa, Ughurlarning gosh mayni kop istimal qilish, haraq tamakigha
kop birilish, beden chiniqturushqa ehmiyet bermesliktek bezi nachar
turmush adetliri sewibidin yuqurda dep otken “baylar kisili”mu kop
uchuraydu.

Uyghur ilining keng yiza qishlaqlirida kishilerning kembighelliqi,
yashash sharahitining nacharliqi, tazliq ingining towenliki, yimek
ichmikining bolupmu ichimlik suyining bulghunishi we yaki bulghanghan
sularni istimal qilishqa mejbur bolushi, we yaki olchemge toshidighan
pakiz suning yiterlik bolmasliqi, bezilerning hetta yoqsuzluq
tupeylidin yiterlik ozuqluqqa irishelmesliki qatarliq seweplerdin
yuqarda dep otken “kembigheller kisili” kop uchursa, Urumchi, Ghulja,
Qeshqer qatarliq chong sheherlerde, kishiler tugimes olturash we
qatar chaylarda chong yep chong ichip, heddidin ziyade kop haraq we
tamakilargha birilgenligi sewibidin yuqurda dep otken “baylar kisili”
dinmu teng “behriman” bolmaqta.

Men deslepte dep otkendek bu bimar tebirkiloz sewibidin kokrek
boshluqigha su yighilip qalghan iken. Dawalashta eng muhimi shu
kokrekke su peyda qilghan tebikilozni uzul kisil dawalash, peqet
shundaq qilghanda, andin nurghun yaman aqiwetlerning kilip
chiqishidin saqlanghili bolidu.

Tebirkiloz Uyghurlar ichide eng  kop uchuraydighan kisellerning biri
bolup, bu kiselni dawalash usuli jehette putun dunya miqyasida chong
periq yoq, hem shundaqla hazir qoliniwatqan dawalash usuli we
dawalashta ishlitilidighan dorilardimu asasen qiliplashqan yaki
formulalashqan. Bu kisel Uyghurlar arisida kop uchurghanlighi uchun
Uyghur ilidiki doxturlarning bu kiselni dawalashtiki tejirbisimu
xilila mukemmel. Undin bashqa tebirkiloz meyli qaysi organ we ezada
bolushtin qetti nezer, dawalash usili putunley oxshash. Adette 3 xil
yaki 4 xil Tebirkilozgha qarshi dorini birleshturup kem digende 6
aydin 9 ay ishletse bolidu. Ayrim ehwalda yaki beden berdashliq
bireligen ehwalda eng yaxshisi 1 yildin 1.5 yil ishletish kirek.
Bundaq qilghanda kiselning uzul kisil saqiyishigha we kiyin yene
qayta qozghulush ihtimalini towenlitishke bolidu. Tebirkilozni
dawalashta ishlitilidighan dorilarning ekis tesiri kushluk bolup,
bedendiki nurghun organ we ezalargha ziyini bar, biraq tebirkilozni
dalashta ishletmey amal yoq. Shunga dawalash jeryanda Jigerni
qoghdash dorilirini qoshumche qilip ishlitish bilen her bir ayda
hich bolmighan her uch ayda jigerni tekshurtup turush kirek.

Kilip chiqish ixtimali bolghan egeshme kisellik we yaman aqiwetler

1. Kokrek perdisining chapliship qilishi (胸膜粘连)
2. Tebirkilozluq Qosaq Perde Yallughi (结核性腹膜炎，腹膜腔结核)
3. Qosaq perdisining chapliship qilishi (腹膜粘连)
4. Qosaq towen qismi tebirkilozi (结核性盆腔炎，盆腔结核 )
5. Uchey Tebirkilozi (肠结核)

Mining tekliwim:

1. Aldi bilen choqum uzul kisel dawalash ilip barsun, amal
bolsa dorini 1 yildin 1.5 yil ishletsun. Hich bolmighanda 9 ay
ishletsun.
2. Ozuqluq kucheytilsun. Amal bar quwetlik tamaqlarni yisun.
3. Yaxshi aram alsun, bek hirip charchashtin saqlansun. Muhapiq
herket qilip bersun.
4. Kisel toluq saqayghiche bala almisun. Kisel saqiyip, dora
ishlitish toxtighandin kiyin kem digende 3, 4 ay otkuziwitip andin
bala ilishqa pilan qilsun. Chunki eghir ayaq bolup qalsa, bu
dorilarni ishlitishke bolmaydu, hem bu dorilarni ishlitiwatqandaq
eghir ayaq bolup qalsa, baligha xeterlik.
5. Toy qilish ishigha kelsek, bu kiselning toy qilishigha
dexlisi yoq, biraq melum jehette yuqumlunush ihtimali bar, undin
bashqa toy qilghandin kiyin kisel saqayghiche bala almasliqning
charisini qilishqa choqum kapalet qilish kirek.

(Aldin qitim sual sorighan tordashtin kelgen xet)

Essilam yaxshimu Siz

Xetingizni tapshurup aldim. waqit chiqirip yazghan jawabingizgha kop rehmet. bu
toghurluq yene bezi mesililerni sizdin dawamliq sorashqa ruxset qilsingiz..

bashtiki sualning tepsilati towendikiche idi:

Bu kesel Mening bir yeqin tuqqinim bolup, u 2006-yili 10-ayda zukamdin bolghan
keyinki hotel awup ketip opkini rentigin'ge elip tekshurtkende , Doxturning
diagonozi peqet zukamdiki hotel bolup bashqa alamet korilmigenti. arliqtin 2
aydek waqit otup 2007-yili 1-ayda u yene bir zukam bolup hotel ewjep ketken hem
bedende azraq qizish bolghan... keyin u ozidiki bu alametlerni yenla zukamdin
bolghan dep zukam darisi we hotel dariliri yep 2 heptidek otup ketken. biraq
hotel yene saqaymighan . bolupmu kechisi hotel bekrek bolghan.3-heptisi yurek
siqilghandek , we dem siqilish qizish ewjep ketkende doxturxanigha yene nechche
qetim korin'gen biraq doxtur bu ehwallargha eniq diagonoz qoyalmighan. yene bir
nechche kun otkendin keyin . ong terep ashqazan aghrighandek bolghanda, ashqazan
aghridi dep perez bilen B chaw gha chuship tekshurtken. netijide ashqazan saq
chiqip ong terep opke astigha 40 ml su chuship qalghanliqi eniq bolghan.hem
qosaq tereptimu az miqdarda su barlighi eniqlan'ghan. shundaq qilip ilgiri axiri
bolup kop qetimliq rentegen we B chaw tekshurushler bolghandin keyin 2.ayning
7-kuni opke doxturxanisida opkidiki suni neyche kirguzup tartqan  we shu
jeryanda tekshurush jeryanda , belekke sinaq netijiside tebirkiliyoz xaraktirlik
kokrek yallughi sewebtin opkige su chuship qalghan dep diyaginoz
qoyuldi.(结核性胸摸炎，右肺下积水） su tartish jeryanda
来里心，作克，葡萄糖+盐酸乙按丁酷，投包。。。。 qatarliq okullarni ishletken.
darilardin.异烟肼片，盐酸乙按丁酷片，利福喷丁胶囊，（yene bir darining ismini
untip qaptimen) bulargha qoship yene jiger'ge tesir yetmeslik uchun,
护肝颗粒，肌肝片 qatarliq darilarnimu qoship ichken.... u burundin adettiki
zukam bolup qalsimu peqet dara yimey oz beden kuchidin keselni qayturup, peqet
dara yimeyttin. okulmu urup ketmeytti. shunga bu qetim 23 kun okul ordi we
darilarni hazirmu yewatidu. doxturning diyishiche darilarni tunji qetimliq
dawalash bolghanliqi uchun az digende 6-9 ayghiche yiyishi kerekken.... dara we
okullarning tesiridin bu qiz doxturxanidin chiqqanda putun bedende maghdur yoq ,
bedem boshap ketkendek, ezilipla qalghandek bir solghun haletke kep qalghanti.
tamaqning kuchlik bolishi dem elish yaxshilinish  bilen hazir chirayigha xeli
qan yugurdi.... (baldurraq burunqi saq jushqun halitige qaytqusi)

Mening bu jeryanlarni sizge yezishimdiki sewep bu qiz texi toy qilmighan. bu yil
axirida toy qilmaqchi. ozi bu yil 33 yashta . mushundaq sharaitta bu qiz yeqin
nechche ay ichide ehtimal 8-9 aylarda toy qilsa muwapiq kelemdu? toy qilishi we
ewlad qaldurushi uchun ishletken dariliri we okulliri keyinlikte tesir qilamdu
yoq. nawada tesir qilsa qanchilik derijide qandaq alametler bolidu. buning
aldini elish uchun bu qiz qandaq qilish kerek. .....

qosaqqa chushken su bashqa jaylargha mesilen balayatqu qatarliq jaylargha tesir
bolishi mumkinmu? doxturxanidin chiqqanda qosaqtiki su 5ml etirapida qaptu
asasen yoq boptu. opkidiki su 12ml bolup dawamliq zhongyi dariliq tok qaqlashqa
we tuzni qorup issiq otkuzup berish qatarliq yerlik usullarni qollan'ghanda
putunley saqiyip ketish ehtimallighi 95% bolidu digen.hazir u qiz oyde kunde
digudek tuz , seriq teriq qatarliqlarni qorup issiq otkuzup darilirini yep
dawamliq dawalinish basquchida....

yoqarqi suallarni sorashtin sirt yene bir sual: bu qiz texi toy qilmay we
baliliq bolmay turup bu kesel bilen dawalinip beden'ge nurghunlighan ximiyilik
darilar singdurdi. mushundaq sharaitta toy qilishqa toghra kelgende u qiz yene
qaysi tereplerde doxturgha tekshurutishi zorurdu?

Sizni yene aware qilidighan boldum.

Find Your Environment

This exercise will help you determine what types of things help or
hinder your own creativity.

First, think about your current conceptual productivity and rank it
on a scale of 1 to 10. This will serve as a benchmark to determine
improvement in the future. Now, get a piece of paper and describe the
most ideal environment that you can imagine. If you could design and
build the perfect office or study, what would you do? Think about
lighting, noise, temperature, access to materials, access to food,
collaboration with friends and co-workers, communication, etc.

Once you are done, compare this perfect environment to the one in
which you currently work. What small changes could you make to move
your current space toward your ideal? Make these changes. Once you
have used the new space for a while, rank your productivity again and
see if it has improved.

If you work in a group, have everyone do this exercise (anonymously
if desired) and see what the team has in common. If you implement
these common requests, you'll be boosting the productivity of
everyone involved.

Creative Environments

Your environment has a big impact upon your creative ability. If you
work in a cubicle with perfectly white walls, boring furniture and
elevator music, your creativity is probably going to be stifled.

Each person has his or her own particular environment that fosters
performance. Some people do better in cold rooms, some in hot rooms.
Some people like music, and others require silence. Some additional
factors that affect performance are windows, lighting, color,
decorations, food and drink, size of space, etc.

If you work in a group, try to be sensitive to the needs of your
teammates. If you know that someone works best in silence, try to
keep your music down (or use headphones). If some people work well on
a sugar high, bring cookies and soda into your brainstorms. Simple
changes around the office or classroom can have big effects on how
people function in those spaces.

美国食品和药物管理局6日批准瑞士诺华公司研制的治疗高血压新药Tekturna上市，
这是药管局批准的第一种肾素抑制剂类高血压治疗药物。

     据介绍，Tekturna是一种新分子实体，通过抑制与血压调节有关的肾素发挥作
用。它能够在血压调节过程刚开始时就发挥作用，而目前其他高血压治疗药物都是在
血压调节过程的后期才能起作用。

     药管局说，Tekturna在降血压方面的安全性和有效性已经在6项临床实验中得到
了验证，其降血压效果可持续长达1年。如果与利尿降压药氢氯噻嗪联合使用，降压效
果更为明显。

     服用Tekturna最常见的副作用是出现腹泻。药管局警告说，孕期妇女禁用此药，
因为可能会伤害胎儿甚至造成死胎。

     高血压被人们称作“无声杀手”，因为它发病初期通常不表现出明显症状，发展
极其隐蔽。药管局在声明中说，估计有大约四分之一的美国人受到不同程度的高血压
影响，高血压也使得患者出现卒中、心脏病、肾衰竭、心力衰竭等疾病的几率增加。

在公司的新闻公告中，Tekturna被称为10多年来新一代的高血压治疗药品，是第一个
肾素抑制剂类的血压控制药物。临床研究共有6400名患者参与，结果显示能够在24小
时内显著降低血压，患者有很好的耐受性。美国是第一个批准Tekturna上市的国家。
Tekturna为口服片剂，一天一次，有150mg和300mg两个剂量片。

Tekturna (Aliskiren) tabiliti dep atalghan yuquri qan bisimining
yingi dorisi FDA teripidin testiqlanghan bolup, qan bisimini
towenlitish roli burunqi herqandaq dorilar bilen silishturghanda hem
tiz hem unumluk iken. Bu dorini ishletkende bashqa qan bisimini
towenlitidighan dorilarni qoshumche qilip ishletmisimu bolidiken.

FDA Approves New Drug Treatment for High Blood Pressure

FDA News http://www.fda.gov/bbs/topics/NEWS/2007/NEW01580.html

The U.S. Food and Drug Administration (FDA) today announced the
approval of Tekturna (aliskiren) tablets for the treatment of high
blood pressure, or hypertension, which affects an estimated 25
percent of Americans and causes increased risk of stroke, heart
attack, kidney failure, heart failure and death.

Tekturna, a new molecular entity (NME), is the first high blood
pressure drug approved by FDA that inhibits renin, a kidney enzyme
associated with the regulation of blood pressure. Tekturna acts at
the beginning of the blood pressure regulation process, while other
available high blood pressure medications act at later stages.

"Hypertension is rightly called "the silent killer" because it
usually has no symptoms until it causes major damage to the body
organs," said Douglas C. Throckmorton, M.D., Deputy Director of
FDA"s Center for Drug Evaluation and Research. "Today"s approval
adds a new safe and effective treatment option for people who need
help to control their blood pressure."

The effectiveness of Tekturna in lowering blood pressure has been
demonstrated in six placebo-controlled eight-week clinical trials,
which studied more than 2,000 patients with mild to moderate
hypertension.

The effect was maintained for up to one year. Tekturna was effective
across all demographic subgroups, but African American patients
tended to have smaller reductions in blood pressure than Caucasians
and Asians, as is generally true for drugs that affect the renin-
angiotensin system, a component of blood pressure regulation.

When Tekturna was used in combination with hydrochlorothiazide, a
diuretic, further reductions in blood pressure were achieved.

Tekturna was evaluated for safety in more than 6,460 patients,
including 1,740 who were treated longer than six months, and more
than 1,250 for over one year. Side effects were usually mild and
brief. The most common side effect experienced by patients taking
Tekturna was diarrhea. Diarrhea was reported by approximately 2
percent of patients on the higher of the two approved doses,
compared with approximately 1 percent on placebo. Rarely, patients
taking Tekturna developed an allergic reaction with swelling of the
face, lips or tongue and difficulty breathing, as has been seen with
other drugs for high blood pressure that act directly on the renin-
angiotensin system.

Tekturna and other drugs that act directly on the renin-angiotensin
system should not be used during pregnancy because they can cause
injury and even death to the developing fetus.

Tekturna is manufactured by Novartis Pharmaceuticals Corp., East
Hanover, N.J.

Mezi Bizi digen nime?

Mezi Bizi (prostate gland丆`O楍`B) erlerning arqa teret yolining
aldigha, dowsining towen terpige we suduk yolining etirapigha
jaylashqan jinsi bez bolup, suduk yolini orap turidu. Chongluqi yingi
tughulghan bowaqning 1.5 giram etirapida, balaghetke yetkende 11
giram etirapida, 25 yashqa barghanda 18 giram, 70 yashqa barghanda
tehminen 31 giram etirapida bolidu. Uning asasliq roli jinsi suyuqluq
ajirtip chiqirish bolup, bu bez ajirtip chiqarghan jinsi suyuqluq
meni (seman) ning 15% teshkil qilidu. Mezi Bizi texminen 50 parche
ushshaq bezchilerdin tuzulgen bolup, neychiler arqiliq suduk yolighan
tutushidu.

Mezi Bizi kisili digen qandaq kisel?

Mezi bizi kisili diginimiz mezi bizide bolidighan kiselliklerning
hemmisining oz ichige alidighan bolup, ular mezi bizi yallughi,
yaxshi supetlik mezi bizi osmisi, mezi bizi raki, mezi bizi
tubirkuluzi, mezi bizi tishi, mezi bizi yiringliq ishshiqi, mezi bizi
haltiliq ishshiqi qatarliq kiselliklerni oz ichige alidu. Ularning
ichide mezi bizi yallughi bilen yaxshi supetlik mezi bizi osmisi
yurtimizda eng kop uchuraydighan bolup, adette kishiler dewatqan mezi
bizi kisili asasliqi mushu ikki kiselni korsitidu. Undaqta mezi bizi
yallughi we yaxshi supetlik mezi bizi osmisi digen qandaq kisel?

Bir tordash mendin towendiki ikki soalni sorighan iken. Men u
tordashqa yazghan jawabimni bashqilarning paydilinishi uchun
gurpidikilergimu ewettim.

1. Ademning opkisige soghuqtin su chuship qalghanda kop miqdarda
bolsa neyche bilen tartip chiqiriwetidiken. nawada az miqdarda bolsa
dara bilen yaki tokqa qaqlap we yaki tuz we bashqa issiqliq otkuzush
arqiliq putunley taziliwetkili bolamdu?  neyche bilen tartiwetkendin
keyin opkide yene az miqdarda qalduq su qep qalsa bu suni qandaq
usulda putunley pakize taziliwetkili bolidu? (Adem tenini dawalash
sewebidin tokqa qaqlap berish toghrimu? tokqa uzaq muddet qaqlap
bergende adem bedinide binormal inkaslar bolup qalamdu?)

Mining ugenginim Gherip Tibabetchiligi bolup, Gherip
Tibabetchiligide “ademning opkisige soghuqtin su chuship qilish”
digen uqum yoq. Elwette bizde mushundaq deydighan adet bar, belkim bu
bir xata chushenche bolushi mumkin, yaki Uyghur Tibabetchiligide
shundaq atalghu bolushi mumkin (buni men taza bilmeydikenmen). Meyli
bu adet qandaq kelgen bolsun, bu xuddi “kozungge qarap
mangmamsen”, “qarangguni tosmighin”digendek xata atalghu.

Gherip tibabetchiligide mushuninggha yiqin kilidighan ikki xil ehwal
bar.

Birinji ehwal: Opke suluq ishshiqi (Pulmonary edema, 肺水肿). Bu bir
xil kisel bolmastin belki nurghun kisellerning egeshme alametliri.
Opke yallughi, Opke Raki, Borek Zeyipliki, Yurek Zeyipliki qatarlqi
kisellerde opke suluq ishshiqi kilip chiqidu. Bu xil opke suluq
ishshiqini dawalashta, asasliqi esli kiselni dawalash asas qilinidu.
Yeni esli kisel dawalap saqaytilsa, opke suluq ishshiqimu saqiyip
kitidu. Men bu yerde tepsile toxtalmaymen.

Ikkinji ehwal: Kokrekke su yighilip qilish (thoracic fluid
accumulation or Pleural fluid accumulation, 胸腔积液). Bumu bir xil
kisel bolmastin belki nurghun kiselliklerde korilidighan egeshme
kisellik alimiti. Kokrekke su yighilip qilish adette kokrek yaki
opke, yurek opiratsiyesidin kiyin, Opke Raki, Kokrektiki bashqa rak
kisili, Opke tibirilkuruz kisili qatarlqi kiselliklerde eng kop
korilidu. Kokrekke su yighilip qilishni dawalashta, esli kiselni
dawalash bilen bir waqitta yighilip qalghan suning az koplikige
asasen yingne bilen tartip ilish, neyche bilen tartip ilish qatarliq
dawalashlar ilip birilidu. Az miqtardiki su, esli kisel konturul
qilinghandin kiyin ozligidin bara bara yoqap kitidu. Alahide eskertip
otushke erzidighan bir nuqta, eger esli kisel yaxshi konturul
qilinmisa, yeni suning kilish menbesi yaxshi konturul qilinimisa,
suni neyche bilen tartip ilish, pewetla waqitliq bolup, su tartip
ilinghandin kiyin uzungha qalmay yene qayta peyde bolidighan gep.
Shunga eng muhim esli kiselni dawalap yaxshi konturul qilish tiximu
muhim.

Tokqa qallash we issiqli otkuzup dawalash toghurmu digende, bu
kiselning qandaq kisellikige baghliq. Nurghun ehwallarda tokqa
qallash we issiqli otkuzup dawalash usuli bolsa bir xil tenherqi
erzan, ekis tesiri towen, fixikiliq dawalash usuli bolup, muhapiq
ishlitilgende, yaxshi unumge irishkili bolidu.

2. Soghuqtin qosaq ichige az miqdarda su chuship qalsa. buni neyche
arqiliq tartqili bolmisa , bu az miqdardiki suni qandaq qilip
taziliwetkili bolidu? qosaqtiki suni pakize taziliwetmigende qandaq
ehwallar korilishi mumkin.? qosaqqa su chuship qalghanda qaysi
tereplerde dawalash ilip barsa bolidu we yaki qaysi tereplerde diqqet
qilish kerek.

Gherip Tibabetchiligide “soghuqtin qosaqqa su chuship qilish” digen
uqum yoq. Elwette bizde mushundaq deydighan adet bar, belkim bu men
bashta dep otkendek bir xata chushenche bolushi mumkin.

Qosaqta normal ehwal astida az miqtarda su bolidu. Adette
diyiliwatqan qosaqqa su yighilip qilish (Abdominal fluid
accumulation, 腹腔积液, 腹水). Bumu bir xil kisel bolmastin belki nurghun
kiselliklerde korilidighan egeshme kisellik alimiti. Qosaqqa su yighilip qilish
adette qosaq opiratsiyesidin kiyin, Qosaqtiki
herqandaq ezada bolidighan rak kisili, yurek zeyipliki, borek
zeyipliki, ozuqluq yitishmeslik (yeni aqsil towenlik) qatarlqi
kiselliklerde eng kop korilidu. Qosaqqa su yighilip qilishni
dawalashta, esli kiselni dawalash bilen bir waqitta yighilip qalghan
suning az koplikige asasen yingne bilen tartip ilish, neyche bilen
tartip ilish qatarliq dawalashlar ilip birilidu. Az miqtardiki su,
esli kisel konturul qilinghandin kiyin ozligidin bara bara yoqap
kitidu. Alahide eskertip otushke erzidighan bir nuqta, eger esli
kisel yaxshi konturul qilinmisa, yeni suning kilish menbesi yaxshi
konturul qilinimisa, suni neyche bilen tartip ilish, peqetla waqitliq bolup, su
tartip ilinghandin kiyin uzungha qalmay yene qayta peyde bolidighan gep. Shunga
eng muhim esli kiselni dawalap yaxshi konturul qilish tiximu muhim.

B tipliq jiger yallughi virusi (BHV) jinsi munasiwet arqiliq er ayal arisida oz
ara yuqqanlighi uchun, beziler B tipliq jiger yallughi kiselini AIDS kisilige
oxshash jinsi yuqumluq kiseller katigoriyesige qoymaqta. Eger er ayalning her
qandaq birsi B tipliq jiger yallughi kisilige giriptar bolghan bolsa, jinsi
munasiwet arqiliq oz ara yuqushi mumkin.

Ayal B tipliq jiger yallughi kisilige giriptar bolghan bolsa, ayal eghir ayaq
bolghanda we yaki bala tughush jeryanida qan arqiliq B tipliq jiger yallughi
virusi (BHV) ni baligha yuqturush ihtimali bar. Bu yerde dimekchi bolghunum
peqet ihtimalliq, choqum yuqudu we yaki choqum yuqmaydu dep kisip eyitmaq qiyin.

Uch kichik musbet we uch chong musbet digenler nimilerdin ibaret?

Uch kichik musbet "xiao san yang" digini B Tiptiki Jiger Yallughi
virusi bilen yuqumlanghan kishilerning qan tekshurush netijiside
HBsAg (+), HBeAb (+), HBcAb (+) bolghan ehwalni korsitidighan bolup,
buning ichide HBsAg (+) antigen bolup ziyanliq, HBeAb (+) bilen HBcAb
(+) antibody bolup paydiliq; Bu xil ehwalda bimarda hichqandaq kisellik alamiti
yoq bolup, herqandaq dwalash arqiliq HBsAg (+) yoq qilish alahide tes. Bu xil
ehwalda dora bilen alahide dawalash ilip birishning orni yoq hem shundaqla
dawalitay disimu hichqandaq unumluk dora yoq. Shunga bundaq ehwal astida muhapiq
beden chinuqturush bilen bedenning imiuyunut kuchini ashurushni asasliq orungha
qoyush kirek.

Adette herqandaq virus adem bedinige kirgendin kiyin hujeyre ichide
kopiyidighan bolghachqa, meyli u adettiki zukam virusi bolsun, jigger
kisili virusi bolsun, yaki ighirsi AIDS kisilini kelturup
chiqiridighan HIV virusi bolsun, dawalashta unumluk dora yoq. Yeni
hazirgha qeder adem bedinige kirgen virusni yoq qilidighan dora yoq.
Hazir dawalashta ishlitiliwatqan virusqa qarshi dorilar (antiviral
medication) ning kopunchisi virusning kopiyishini  (replication)
tosaydighan bolup, virus kopiyishtin toxtighanda, qanni tekshurse
negative (-) chiqidu, biraq bu u virusning adem bedinidin
yoqalghanlighidin direk bermeydu. Adette bundaq ademde hichqandaq
kisel alameti bolmaydu, biraq bu ademning jigiri virus teripidin asta
asta dawamliq zehmilendurulishi mumkin. Undin bashqa adem bedini
ajizlashqanda, yaki uzun muddet hirip charchap ketkende, jiger kisili
qayta qozghulishi mumkin. Bu chaghda qanni tekshurse HBeAg (+)
chiqidu. Bu chaghada dora ishlitip, virusning kopiyishini konturul
qilsa bolidu.  B Tiptiki Jiger Yallughigha dora ishlitishning olchimi
HBeAg (+) bolush; eger HBeAg (-), HBsAg (+), bolsa dora ishletmisimu
bolidu. Emiliyette hazirghiche hichqandaq bir dorining HBsAg (+) ni
HBsAg (-) ge aylanduralaydighanlighi ispatlanghini yoq. Jungguoda bu
xildiki dorilar nahayti kop bolup, eger sinap baqay dise, ihtizadi
ehwali yar bergen ehwal astida sinap baqsa bolidu. Bolupmu milliche
yaki Jongyi usulida bezi dawalashlarni sianq terqqiside ilip barsa
bolidu. Chunki bumu bir izdinish. Ilim pen izdinish netijiside andin
ilgirleydu. Izdinish bolmisa bu kiselge menggu dora tipilmasliqi
mumkin.

Bezi kishilerning HBsAg (+) si bir mezgildin kiyin HBsAg (-) ge
aylanghanlighi melum, biraq mining qarishimche bu birer dorining
unimidin emes, belki bimarning imunut kuchi yaxshilinip, virusning
ustidin ghalip kelgenligidin. Huddu kishiler zukamgha giriptar
bolghanda dora yimisimu 5, 6 kundin kiyin ozligidin saqayghinigha
oxshash. Adette kishiler zukam bolghanda ishletken dorilarning
paydisi zukam peyda qilghuchi virusni bedendin yoqutush emes, belki
kisel alametliri yenggillitish, bimarni kisellik kelturup chiqarghan
biaramliqtin qutuldurush. Deslepte dep otkendek hazirgha qeder
bedenge kirgen virusni yoq qilidighan dora yoq. Eger bedenge kirgen
virus yoq boldi digende, u dorining tesiridin emes belki bedenning
kiselge qarshi turush kuchining virus ustidin ghalip kelgenligining
netijisidindur. Adette virustin peyda bolghan kisellerni dawalashta,
doxturlar kopunche halda yardemchi dawalash wastisi qollunidu.

Bu kisel yuqumluq kisel bolup, gerche "xiao san yang"ning
bashqilargha yuqushning ihtimali sel towen bolsimu, biraq putunley
yuqmaydu digili bolmaydu. Jiger yallughuning hemmisi yuqumluq kisel
qatarigha kiridu. Wetende bolupmu jenupta bu kisel kop bolup, burun
nurghun kishiler olup ketken. Yiqindin buyanqi ehwal sel yaxshi.
Jungguoning omumi yuzluk ehwalini alsaq, mining qarishimche kem
digende 30% ademning qinida HBs-Ag (+) bolushi mumkin. Burun bilimlik
kishiler HBs-Ag (+) kishilerge ighir qarayti hem ozige yuqup
qilishtin bek ensireyti, undaq kishiler bilen arlishishtin qachatti,
hazir kishilerning bu kiselge bolghan tonushi yuquri koturulgenligi
we qandaq qilip oz ara yuqushni konturul qilishni bilgendin kiyin, bu
kiseldin anche qoruqmaydighan boldi. Shundaqtimu yenila ihtiyat
qilghan yaxshi, bolupmu bimarning ozi ozini ozi sorap, bashqilargha
yuqturup qoyushtin kop diqet qilish kirek. Bu kisel adette asasliqi
qan arqiliq yuqidighan bolup, jinsi suyuqluq, sholgey, beden
suyuqliqidinmu yuqush ihtimaliqi bar. Bu kisel gerche adettiki
uchurshushlar arqiliq yuqmisimu, biraq qoyuq arlishish arqiliq
yuqushi yenila mumkin. Bolupmu HBeAg (+) bolghanda bashqilargha
yuqush ihtimali nahayti yuquri. Shunga ezeldin jiger kisilige
giriptar bolmighan kishilerning qinidin HBs-Ag (+) chiqishi shu
seweptin. Dimekchi bolghunum nurghun kishiler bile bilmeyla
bashqilardin jiger kisili virusini ozige yuqturiwalghan. Ozini
qoghdashta eng yaxshi usul, muhapiq beden chiniqturup, bedenning
imiyunut kuchini ashurush. Bashqilargha yuqturup qoyushtin saqlinish
uchun eng yaxshisi shexsi boyumlarni bolupmu saqal alghuch, chish
chotkisi, longge, qacha qucha digenlerni ayrim ishlitish kirek.

Undin bashqa qerelik saghlamliq tekshurtush, kem digende bir ikki
yilda bir qitim qan arqiliq jigerning iqtidarini tekshurtup turush we
B Chao arqiliq jigerni tekshurtup turush kirek. Yishi 40 yashtin
yuquri kshiler tekshurushning waxtini sel qisqartishi, hem shundaqla
qandin AFP nimu qoshumche qilip tekshurtup turushi kirek. Hirip
charchashtin saqlinish, salametlikige alahide diqet qilish kirek.

Rak kisilige munasiwetlik sanliq melumatlar

Rak kisilini dawalashta gerche nurghun ilgirleshler bolghan bolsimu,
biraq u yenila kishilerning olup kitishidiki eng asasliq sewep
hisaplinidu. 2005-yili putun dunyada texminen 58 miliyun kishi her
xil kisellikler tupeylidin olup ketken bolup, ularning ichide 7.6
miliyun kishi rak kisili tupeylidin olup ketken. Hazir kishilerning
olushige sewep bolghan rak kisilining ichide eng kop uchuraydighan
raklar towendikilerdin ibaret.

Opke raki (yiligha texminen 1.3 miliyun ademning olushini kelturup
chiqiridu)
Ashqazan Raki (yiligha texminen 1 miliyun ademning olushini kelturup
chiqiridu)
Jiger Raki (yiligha texminen 662ming ademning olushini kelturup
chiqiridu)
Chong uchey raki (yiligha texminen 655ming ademning olushini kelturup
chiqiridu)
Emchek (koksi) raki (yiligha texminen 502ming ademning olushini
kelturup chiqiridu).

2005-yili rak kisili bilen olup ketken bu 7.6 miliyun ademning 70%
ixtizadi tereqqi qilmighan kembighel doletlerdin bolup, 2015-yiligha
barghanda bu san 9 miliyungha yitidiken. Buning asasliq sewibi
tereqqi qiliwatqan dowletlerdi tamaka chekkuchilerning kunsayin
kopiyishi, dawalash sharaitining nisbeten towen bolushi qatarliqlar
iken.

FACTS ABOUT CANCER

Cancer is a leading cause of death worldwide. From a total of 58
million deaths worldwide in 2005, cancer accounts for 7.6 million (or
13%) of all deaths. The main types of cancer leading to overall
cancer mortality are:
昹ung (1.3 million deaths/year);
昐tomach (almost 1 million deaths/year);
昄iver (662,000 deaths/year);
旵olon (655,000 deaths/year) and
旴reast (502,000 deaths/year).
More than 70% of all cancer deaths in 2005 occurred in low and middle
income countries. Deaths from cancer in the world are projected to
continue rising, with an estimated 9 million people dying from cancer
in 2015 and 11.4 million dying in 2030.